[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Next Article in Journal
Chemical Composition and Antioxidant, Antiviral, Antifungal, Antibacterial and Anticancer Potentials of Opuntia ficus-indica Seed Oil
Next Article in Special Issue
Drimane-Type Sesquiterpenoids Derived from the Tropical Basidiomycetes Perenniporia centrali-africana and Cerrena sp. nov
Previous Article in Journal
Current Use of Fenton Reaction in Drugs and Food
Previous Article in Special Issue
Natural Products in Mitigation of Bisphenol A Toxicity: Future Therapeutic Use
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 17
10.3390/molecules27175452
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Combination Anticancer Therapies Using Selected Phytochemicals

by
Wamidh H. Talib
1,*,
Dima Awajan
1,
Reem Ali Hamed
1,
Aya O. Azzam
1,
Asma Ismail Mahmod
1 and
Intisar Hadi AL-Yasari
2
1
Department of Clinical Pharmacy and Therapeutic, Applied Science Private University, Amman 11931-166, Jordan
2
Department of Genetic Engineering, College of Biotechnology, Al-Qasim Green University, Babylon 964, Iraq
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(17), 5452; https://doi.org/10.3390/molecules27175452
Submission received: 29 June 2022 / Revised: 17 August 2022 / Accepted: 22 August 2022 / Published: 25 August 2022
(This article belongs to the Special Issue The Role of Natural Products in Promoting Well-being: From Foods to Drugs)
Browse Figures
Figure 1
<p>Chemical structure of curcumin.</p> "> Figure 2
<p>Chemical structure of resveratrol. (<b>a</b>) <span class="html-italic">Trans</span>-resveratrol and (<b>b</b>) <span class="html-italic">Cis</span>-resveratrol.</p> "> Figure 3
<p>Chemical structure of genistein.</p> "> Figure 4
<p>Chemical structure of EGCG.</p> "> Figure 5
<p>Chemical structure of allicin.</p> "> Figure 6
<p>Chemical structure of thymoquinone.</p> "> Figure 7
<p>Chemical structure of piperine.</p> "> Figure 8
<p>Chemical structure of emodin.</p> "> Figure 9
<p>Chemical structure of parthenolide.</p> "> Figure 10
<p>Chemical structure of luteolin.</p> "> Figure 11
<p>Chemical structure of quercetin.</p> "> Figure 12
<p>Chemical structure of anthocyanins (cyanidin).</p> "> Figure 13
<p>A summary of the natural compounds with their combination therapy. QUR, quercetin; CUR, curcumin; TQ, Thymoquinone; LTN, Luteolin; ACN, anthocyanins; PTL, parthenolide; GNT, genistein; PIP, piperine; EMD, emodin; RES, resveratrol; ALN, allicin; CIS, cisplatin; DOX, doxorubicin; MT, melatonin; TMZ, temozolomide; Tmab, trastuzumab; TAM, tamoxifen; DTX, docetaxel; PTX, paclitaxel; CCB, celecoxib; CAPS, capsaicin; PF, photofrin; SFN, sulforaphane; GEF, gefitinib; ASC, ascorbic acid; ADM, Adriamycin; MSM, methylsulfonylmethane; RJ, royal jelly; PF, pentoxifylline; BV, bee venom; HES, hesperidin; BBR, berberine; SFB, sorafenib; AFT, afatinib; GEM, gemcitabine; ENDX, endoxifen; G-CK, ginsenoside compound k; G-Rh, ginsenoside Rh; EPR, epirubicin; ICG, indocyanine green; ATO, arsenic trioxide; BLZ, balsalazide; SB, silibinin; BCN, baicalein; VIN, vincristine; RT, radiotherapy.</p> ">
Review Reports Versions Notes

Abstract

:
Cancer is still one of the most widespread diseases globally, it is considered a vital health challenge worldwide and one of the main barriers to long life expectancy. Due to the potential toxicity and lack of selectivity of conventional chemotherapeutic agents, discovering alternative treatments is a top priority. Plant-derived natural products have high potential in cancer treatment due to their multiple mechanisms of action, diversity in structure, availability in nature, and relatively low toxicity. In this review, the anticancer mechanisms of the most common phytochemicals were analyzed. Furthermore, a detailed discussion of the anticancer effect of combinations consisting of natural product or natural products with chemotherapeutic drugs was provided. This review should provide a strong platform for researchers and clinicians to improve basic and clinical research in the development of alternative anticancer medicines.

1. Introduction

Cancer is one of the major public health problems, ranked as the second leading cause of death worldwide [1]. From a statistical perspective, 19.3 million new cases and about 10 million deaths have been reported in 2020 [2]. Cancer and its treatment have a negative impact on the economic resources and the health care system, which requires paying more attention to developing new preventive and treatment strategies with low cost and effective outcomes [2]. Additionally, other factors contributed to cancer being a global burden, including drug resistance and treatment side effects [3,4].
Since cancer is a heterogenous disease, conventional monotherapy has shown limited efficacy in the treatment and prevention [5]. In addition, several anticancer drugs have been associated with prominent undesirable adverse effects such as cardiotoxicity by doxorubicin [6], ototoxicity as a long-term side effect of cisplatin [7], and cognitive impairment by the 5-fluorouracil drug [8]. Hence, plant-derived compounds, known as phytochemicals, have been proved to be a potential approach for discovering new effective and safer anticancer agents [9]. Moreover, phytochemicals can inhibit cancer development via inducing cell apoptosis, modulating the immune response, suppressing angiogenesis factors, and targeting gene expression in cancer [10,11]. In preclinical studies, natural products in combination with chemotherapy have shown an ability to enhance anticancer activity and overcome drug resistance [12,13]. Moreover, it was found that high single doses of natural compound treatment may not be effective as using lower doses in combination anticancer treatment models [5,14]. The advantage of using a combination approach in cancer therapy is represented by targeting different pathways in a distinctively, synergistic, or additive manner [15]. In this context, when designing a combination experimental model, the expected cross-resistance and overlapping adverse effects of these compounds should be taken into account [16].
Many preclinical studies have investigated combination cancer therapies that involved natural product interventions and revealed promising results [5]. Fantini et al. [17] demonstrated how the combination treatment using different polyphenols may conquer its poor bioavailability and consequently increase their activity. On the other hand, six phytochemicals, including indol-3-carbinol, resveratrol, C-phycocyanin, isoflavone, curcumin, and quercetin, have been tested in combination against breast cancer cell lines. The results have shown a synergistic effect in inhibiting cell growth, suppressing tumor cell migration and invasion, and promoting both cell cycle arrest and apoptosis [18].
In this review, we aim to provide comprehensive data on the main effective phytochemicals and demonstrate their molecular mechanisms of action in combination with other plant-derived molecules or chemotherapy. Choosing these phytochemicals was based on their high potential anticancer activity and the extensive evaluation of their effect on improving chemotherapy outcomes.

2. Combination Therapies Based on Selected Natural Products

2.1. Curcumin

Curcumin (CUR) (diferuloylmethane) is a polyphenol that is extracted from the rhizomes of the natural plant Curcuma longa L. (turmeric) [19,20]. It was discovered for the first time in 1870, in a pure crystalline form [20] (Figure 1). Turmeric is one of the most widely used culinary spices in India and Southeast Asian nations, and is widely used in traditional Chinese herbal medicine [21]. Curcumin exerts multiple pharmacological activities including antioxidant, anti-inflammatory, antibacterial, antiviral, and anti-cancer activity. Currently, its anticancer effect has been the most researched [22]. The main challenges facing the use of turmeric are low water solubility and bioavailability [23]. Several structural changes have been made to increase its overall anticancer efficacy and improve selective toxicity against certain cancer cells [23,24].
An in vitro study showed that turmeric with IC50 (31.14 ± 1.24 µM) was effective against MCF-7 cell lines in breast cancer [25]. Moreover, the IC50 of free CUR for 48 h was 5.63 μg/mL in Colon cancer [26]. Zargari et al. demonstrated that IC50 of pure turmeric after 72 h was 13.6 µM in lung cancer [27]. A toxicity study showed that curcumin exhibited limited toxicity when injected intraperitoneally in mice with LD50 value of 1500 mg/kg [28]. The LD50 of curcumin was calculated by Harishkumar et al. and was found to be 135 µg/mL in zebrafish embryos which were transferred to a 24-well cell culture plate [29].
Lower doses of curcumin were used as therapeutic doses in cancer treatment. Fetoni et al. described that curcumin was administered intraperitoneally at three different doses (100, 200, and 400 mg kg−1 body weight) [30]. The administration of a curcuminoid formulation (180 mg/day) as adjuvant treatment for 8 weeks to cancer patients with solid tumors significantly increased life satisfaction and reduced systemic inflammation [31].
Curcumin exhibits anti-cancer activity due to its ability to induce apoptosis, and decrease tumor growth and invasion through the suppression of a range of cellular signaling pathways [32]. Kuttikrishnan et al. demonstrated that 80 μM of curcumin-induced apoptosis in acute lymphoblastic leukemia [33]. Although extensive research has demonstrated that curcumin causes cytotoxicity in cancer cells through a variety of mechanisms. Interestingly, curcumin combined chemotherapy had increased treatment outcomes synergistically [34].
In vitro study had shown that a combination of 5 nm paclitaxel and 5 μm curcumin was highly beneficial for treating cervical cancer [35,36]. This compound enhanced paclitaxel-induced apoptosis by increasing p53 expression, activation of caspase-3, 7, 8, and 9, cleavage of poly(ADP-ribose) polymerase (PARP), and cytochrome c release, as shown by western blot analysis [35,37]. Banerjee et al. suggested that combining curcumin with standard chemotherapy might be an effective treatment strategy for individuals with prostate cancer. Moreover, reducing cytotoxicity and overcoming docetaxel-induced drug resistance. Commonly, long-term docetaxel therapy leads to drug-resistant in metastatic prostate cancer cell lines [38].
Metformin is used as a treatment for noninsulin-dependent diabetes mellitus (T2 DM) [39]. Interestingly, curcumin and metformin had a synergistic inhibition impact on prostate cancer cell line growth due to apoptotic induction [40].
Colorectal cancer has been widely treated with 5-FU alone (10 M) or in combination with other chemotherapy agents [41]. Multidrug resistance was common in individuals with colorectal cancer who were given a 5-FU-based treatment [41]. Thereby, a new therapy to overcome resistance is needed, such as combining 5-FU with curcumin in MMR-deficient human colon cancer cell lines [42]. When compared to celecoxib alone, curcumin with celecoxib inhibited colorectal cancer cell proliferation in vitro [43]. Moreover, in bladder cancer cell lines (253J-Bv and T24), co-treatment of curcumin (10 M) and cisplatin (10 M) stimulated caspase-3 and overexpressed phospho-mitogen-activated protein kinase (p-MEK) and phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) signaling pathways [44]. Guorgui et al. found that combining curcumin (5 M) with doxorubicin (0.4 mg/mL) reduced the growth of Hodgkin lymphoma (L-540) cells by 79% [45].
In vitro and in vivo studies reported that (docetaxel/curcumin copolymers ) are strong anti-tumor candidates with tremendous promise in ovarian cancer treatment [46]. Combination of curcumin and 3-acetyl-11-keto—boswellic acid (AKBA) were shown to have antineoplastic effects in colorectal cancer in vivo. The anticancer mechanism of this combination is mediated through alteration of miRNAs and their downstream target genes involved in cell-cycle control [47].
Curcumin in combination with soy isoflavones inhibited the generation of inflammatory markers (prostate-specific antigen) in the LNCaP prostate cancer cell line [48]. Andrea Arena et al. found that curcumin and resveratrol were equally effective in reducing cancer cell viability in Her-2/neu-positive breast and salivary cancer cell lines. This activity was with different effects on autophagy, ROS, and PI3K/AKT/mTOR pathway activation [49]. Furthermore, this combination resulted in a higher cytotoxic impact, which was related to increased ER stress and activation of the pro-death UPR protein CHOP [49]. Curcumin and Epigallocatechin Gallate (EGCG) combination exhibited several anticancer activities [50]. When combining these two natural polyphenols, a good therapeutic effect was observed in the treatment of bladder, ovarian [51], breast [52], and prostate malignancies [53]. Furthermore, Somers-Edgar et al. had shown that a combination of EGCG (25 μM) and curcumin (3 μM) is synergistically cytotoxic toward MDA-MB-231 human breast cancer cells in vitro and decreases ERα-tumor growing in vivo [54].
In addition, 30 μM curcumin with 80 μM emodin exerted potent actions against breast cancer cell lines. Due to inducing the expression of miR-34a, the tumor growth and invasion had suppressed [55]. Another study examined the synergistic effect of curcumin and thymoquinone (TQ), on the development of MCF7 and MDA-MB-231 breast cancer cell lines [56]. Moreover, this compound and gemcitabine prevented the development, invasion, and metastasis of the pancreatic cancer orthotopic model. Those effects were due to inhibiting angiogenesis, proliferation, and downregulation of NF-κB–regulated gene products [57,58]. Aside from that, they upregulate proteins involved in apoptosis and PC cell inhibition (Bax and caspase) [57,58]. Several studies demonstrated that curcumin appears to interact with vitamin D receptors, which might explain its anti-cancer capabilities in Caco-2 human colon cancer cells [59]. Curcumin and quercetin reduced cancer cell proliferation synergistically in A375 melanoma cells. Modulation in Wnt/β-catenin signaling and apoptotic pathways are moderately responsible for the antiproliferative effects [60].

2.2. Resveratrol

Resveratrol (RES) (trans-3,4′,5-trihydroxystilbene) is a phytoalexin belonging to the stilbene class that occurs naturally. It is normally synthesized by plants in response to injury or when under attack by microorganisms including bacteria or fungi [61]. Even though 72 different plants produce resveratrol naturally, the main sources of resveratrol include wine, grapes, peanuts, pomegranate, pines, cocoa, cranberries, and dark chocolate [62]. The two principal isomers of resveratrol are cis and trans (Figure 2), and they frequently coexist. Moreover, the trans is more biologically active than the cis form [63]. Resveratrol may play an important role in the prevention or treatment of chronic diseases, among its effects are antioxidative, anti-inflammatory, anti-proliferative, and anti-angiogenesis properties, as well as improved cardiovascular outcomes [62,64].
Several studies were conducted to evaluate the toxicity of resveratrol. Against HeLa human cervical cancer cells, RES was active at IC50 value of 83.5 µM [65]. Moreover, HT-29 human colon cancer cells were inhibited by RES at IC50 value of 43.8 μmol/L [66]. RES displayed growth inhibitory activities against HT-29, HCT-116, and Caco-2 human colon cancer cells with IC50 values of 65, 25 and >100 μM, respectively [67]. Jawad et al. reported that the LD50 dose of resveratrol was 1.07 g/kg for males and 1.18 g/kg for females in mice after intraperitoneal administration [68].
Therapeutically, resveratrol (100 mg/kg) was intraperitoneally injected to treat lung cancer cells and the treatment resulted in tumor regression [69]. Based on the results of the previous clinical studies, the recommended dosage of resveratrol for the treatment of colon cancer is 20–120 mg daily for two weeks [70] or 0.5–1 g daily for one week [71], and 5 g daily for two weeks for patients with colorectal cancer [72].
Resveratrol has numerous chemoprotective and cancer therapy mechanisms to prevent, arrest, or reverse carcinogenesis stages. Genome instability, abnormal cell proliferation, abnormal response to signals or stimulators of programmed cell death, increased oxidative stress, overproduction of growth regulator hormones, and changes in the host immune system are among the most important cellular changes. The antioxidant, anti-inflammatory, and immunomodulatory activities also contribute, to reducing the damage caused by oxidative stress (DNA damage, protein oxidation, and lipid peroxidation) and enhancing immune oncosurveillance [73]. Resveratrol inhibits the monooxygenase cytochrome P450 isoenzyme CYP1 A1, the liver enzyme responsible for the metabolism of xenobiotics, as well as acts as a blocking agent by preventing the conversion of procarcinogen to carcinogen [74,75]. Numerous in vitro and limited in vivo studies indicate that resveratrol may augment the antitumor effects of chemotherapeutic drugs in a variety of cancers [76,77]. In addition to its anti-carcinogenic effect, resveratrol is now being studied for its potential as an adjunct in conjunction with chemotherapeutic agents to boost their efficacy and/or limit their toxicity. Using a mouse xenograft model of malignant glioma, Lin and colleagues found that resveratrol enhanced the alkylating agent temozolomide’s therapeutic efficacy by inhibiting ROS/ERK-mediated autophagy and improving apoptosis [78]. Resveratrol in 12.5 mg/kg dose has also been used to reduce chemoresistance in a mouse model of B16/DOX melanoma by inducing cell cycle disruption and apoptosis, resulting in decreased melanoma growth and increased mouse survival [79].
Malhotra and co-workers evaluated the efficacy of curcumin in combination with resveratrol in mice with benzo-a-pyrene (BP)-induced lung carcinogenesis [80]. The study demonstrated that the combination of curcumin and resveratrol enhances chemopreventive efficacy by maintaining adequate zinc levels and modulating Cox-2 and p21 [80]. Resveratrol and melatonin have also been studied in combination, NMU-induced mammary carcinogenesis was not affected by either agent alone, but when they were combined it resulted in a significant decrease in tumor incidence [81]. A combination of resveratrol, quercetin, and catechin to gefitinib can enhance its antitumor and antimetastatic effects in nude mice [82]. These studies support the possibility of using resveratrol in conjunction with chemotherapeutic drugs for cancer management.

2.3. Genistein

Genistein (GNT) (4,5,7-trihydroxyisoflavone) is the dominant isoflavone in soybean-enriched foods, which make up a large part of the Asian diet (Figure 3). A study found that isoflavone levels in the blood were inversely related to the risk of non-proliferative and proliferative benign fibrocystic conditions, as well as breast cancer [83]. At first, genistein was assumed to be a phytoestrogen because its structure was similar to that of estrogens and it had a small amount of estrogenic activity. The main building block of isoflavone compounds is the flavone nucleus, which is made up of two benzene rings connected by a heterocyclic pyrane ring. Due to their similar structures, it has been shown that genistein competes with 17-estradiol in ER binding tests [84].
It was discovered that genistein specifically inhibits EGFR as well as other RTKs with an IC50 value of 22 µM [84]. Another study showed that genistein inhibits the autophosphorylation of EGFR in vitro at an IC50 value of 2.6 µM [85]. The IC50 value of genistein against PLK1 activity was 7.9 µM while the IC50 values of genistein against other TKs, such as erbB2, erbB4, IGF1 receptor, insulin receptor, and PDGFR were over 4000 µM [86]. According to a study, the LD50 of genistein was 1150 mg/kg in mice when given intraperitoneally [87]. In HL-60 cells, genistein reduced the number of cells by causing the G2/M phase to be arrested, induced cell death through mitochondrial and ER stress-dependent pathways, and inhibited tumor characteristics in vivo. Mice were intraperitoneally injected with genistein (0, 0.2, and 0.4 mg/kg) for 28 days in an animal xenografted model and results showed tumor regression in treated animals [88].
Numerous important biological effects of genistein consumption concerning its anticancer properties have been illustrated. Even though, genistein has several health benefits, such as reducing the incidence of cardiovascular disease [89], preventing osteoporosis, and alleviating postmenopausal issues [90]. Genistein is a known inhibitor of the protein-tyrosine kinase (PTK), which may inhibit PTK-mediated signaling mechanisms to inhibit the growth of cancer cells [86]. Transgenic mice that overexpress the HER-2 gene’s tyrosine phosphorylation show delayed tumor development when genistein is given as an oral supplement, according to a study published just recently by the group Sakla et al. This shows that it may have an anti-cancer role in breast cancer chemotherapy [91]. However, it has been shown that other effects are not related to this activity [92]. It is possible that the inhibition of topoisomerase I and II [93], 5α-reductase [94] as well as protein histidine kinase [95], are all part of the mechanism by which genistein acts.
Genistein’s chemotherapeutic mechanism of action has been widely studied in a variety of cancers. Apoptosis, angiogenesis, and metastasis are all mechanisms affected by genistein. The primary molecular targets of genistein involve caspases, B-cell lymphoma 2 (Bcl-2), Bax, NF-B, PI3K/Akt, ERK1/2, mitogen-activated protein kinase (MAPK), and the Wnt/-catenin signaling pathway. Genistein has been shown to induce apoptosis in tumor cells by targeting the PPAR signaling cascade, which has surfaced as another potential therapeutic target for modulating tumor growth [96].
By modulating AMPK and COX-2, genistein with capsaicin exerted synergistic apoptotic and anti-inflammatory effects on MCF-7 human breast cancer cells [97]. It has been shown that genistein exposure for 24 h followed by 48 h of estradiol treatment resulted in the greatest apoptosis in HepG2 human liver cancer cells [98]. The anticancer effects of 5-fluorouracil in MIA PaCa-2 human pancreatic cancer cells were augmented by the addition of genistein, which increased both apoptosis and autophagy. Additional studies on animals transplanted with MIA PaCa-2 cells showed a significant decrease in tumor volume after the combination of treatments [99]. It has also been shown that genistein enhances the efficacy of photofrin-mediated photodynamic therapy to induce apoptosis in human ovarian cancer and thyroid cancer cells [51]. Activation of the general apoptotic signaling cascade required activation of caspase-8 and caspase-3 to regulate these effects [51,100]. Genistein and sulforaphane have a synergistic effect on MCF-7 and MDA-MB-231 breast cancer cells; this combination reduced cell viability, resulting in cell death, as well as cell cycle arrest in G1 phase (MCF-7 cells) and G2/M phase (MDA-MB-231 cells) [101].

2.4. Epigallocatechin Gallate

Many recent studies have focused on examining green tea (Camellia sinensis) and its polyphenolic components; one of the most interesting among these compounds is the Epigallocatechin Gallate (EGCG) (Figure 4). It is believed to have several benefits in the health sector as it has a role in various types of diseases such as cardiovascular diseases, as EGCG inhibits the NF-kappaB (NF-κB), which may be involved in developing heart failure. Additionally, EGCG inhibited myeloperoxidase (MPO) which is known to be elevated in coronary artery diseases (CAD) [102]. EGCG also has a role in metabolic diseases such as Diabetes Mellitus as it can lower the plasma glucose level and glycated hemoglobin level [102]. Furthermore, EGCG can act as an anti-oxidant due to its power in attacking reactive oxygen species [103].
To evaluate EGCG toxicity, a study demonstrated that 13 weeks of EGCG oral administration in rats was non-toxic at doses up to 500 mg/kg/day. However, oral administration of 2000 mg EGCG/kg was fatal. No toxicity was observed at an oral dose of 200 mg EGCG/kg [19]. While another study showed that the ingestion of green tea-derived supplements at a high dose (120 mg/kg) can induce toxic effects such as hepatotoxicity in rodents [104].
Additionally, EGCG has an important role in fighting cancer as it inhibits the initiation, promotion of, and progression phases in cancer cells [105]. Add to that its ability to promote apoptosis. Huang et al. found that 30 µmol/L of EGCG had induced apoptosis in MCF-7 breast cancer cell lines [106]. A study reported that the IC50 for EGCG when used against Eca-109 and Te-1 cancer cells was 256 and 162 μM, respectively [107]. Another article reported that the IC50 for EGCG which inhibited the NDPK-B activity was 150 µM [108]. Furthermore, it had been found that IC50 of EGCG against lung A549 cancer cells was 25 μM [109]. Additionally, reduced cell viability was reported at IC50 values of 14.17 μM for T47D and 193.10 μM for HFF cells [110].
Regarding toxicity, the estimated LD50 of EGCG when administered intradermally in rats was 1860 mg/kg [111]. Moreover, it had shown that EGCG-produced dose dependent cell death with average IC50 equals to 25–50 μg/mL in human B-cell lymphoma cell lines and primary NHL cells [112]. In another study, it had been shown that the IC50 for EGCG was 348 µM when used with A549 cells [113]. According to an in vivo study, ECGC was used in SW780 nude mice xenograft model at a concentration of 100 mg/kg, which was equivalent to a single dose of 487 mg EGCG powder for a 60-kg adult. The results have shown that ECGC successfully inhibited tumor progression in tumor-bearing mice [114]. In addition, treatment with EGCG (50 mg/kg/day, 14 days) diminished the growth of MCF-7 implanted breast tumors in athymic nude mice by 40% [115].
EGCG has an important role in fighting cancer as it inhibits the initiation, promotion, and progression phases in cancer cells [106]. Add to that its ability to promote apoptosis. Huang et al. found that 30 µmol/L of EGCG had induced apoptosis in MCF-7 breast cancer cell lines [107]. Furthermore, EGCG could be used with other anti-cancer treatments, such as natural products and chemo drugs. However, regarding the EGCG effect with natural products, Eom et al. had shown that 50 and 100 μM EGCG use along with curcumin had arrested S and G2/M cycles in PC3 prostate cancer cells [116]. In addition, EGCG improved the anti-metabolic effect of quercetin in ER-negative breast cancers, and also it decreased the viability and proliferation of MCF7 cells [117]. Furthermore, Tan et al. reported that (5, 25, and 50 μg/dL) of EGCG and thymoquinone had decreased the proliferation of PANC-1 pancreatic cancer cell lines [118]. In addition, Chen et al. demonstrated that a combination of EGCG and sulforaphane had provoked apoptosis in ovarian resistant cells in vitro, through human telomerase reverse transcriptase (hTERT) and Bcl-2 down-regulation [119]. Moreover, in vivo study reported that 30 μM EGCG combination with 15 μM resveratrol resulted in enhancing the apoptotic effect and reducing the tumor growth in head and neck cancer [120]. With chemotherapy, Wei et al. had shown that using 20–100 μM EGCG along with 5-fluorouracil (5-FU) and doxorubicin enhanced their ability in growth inhibition and also improve their ability to suppress the phosphorylation of extracellular-signal-regulated kinase (ERK) in multiple cancer cell lines [121]. La et al. also proved that 50 μM EGCG increased DLD1 colorectal cancer cell line’s sensitivity to 5-FU through the inhibition of 78-kDa glucose-regulated protein (GRP78), NF-KB, miR-155-p5, and multidrug resistance mutation 1 (MDR1) pathways [122]. Furthermore, 10 μM EGCG had enhanced cisplatin sensitivity in ovarian cancer cell lines by regulating the expression of copper and cisplatin influx transport which is well-known as copper transporter 1 (CTR1) [123]. Moreover, 100 μM EGCG improved the cytotoxic effects of cisplatin through autophagy-related pathways in an in vitro study [124]. In HeLa cervical cancer cells, 25 μM EGCG had potentiated cisplatin effects as a result of decreasing cell survival and enhancing apoptosis [125]. Though with tamoxifen, EGCG (25 mg kg−1) had lowered the negative estrogen receptor (ER-) in breast cancer cell lines, as it was expected to decrease protein expression of the epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), and cytochrome P450 family 1 subfamily B member 1 (CYP1B) [126]. Moreover, 20 μM EGCG synergistically encouraged the effect of paclitaxel on breast cancer cells as it enhanced the phosphorylation of c-Jun N-terminal kinase (JNK) and the cell death in 4T1 cells [127]. Additionally, 20 μM EGCG had improved gefitinib resistance by inducing cell death by affecting the phosphorylation of EPK as well as the inhibition of epithelial-Mesenchymal transition (EMT) and inhibition of the phosphatidylinositol-3-kinase (PI3K)/mTOR pathway in non-small cell lung cancer (NSCLC) cell lines [128]. Besides this, EGCG had improved the effect of erlotinib in head and neck cancer in vitro. As it enhanced the apoptosis through the regulation of Bcl-2-like protein 11 (BIM) and B-cell lymphoma 2 (Bcl-2) [129].

2.5. Allicin

Allicin (ALN) or diallyl thiosulfinate (Figure 5) is one of the well-known organosulfur compounds that are found in garlic (Allium sativum L.). It can be generated by the cleavage or cutting of the garlic clove which in return activates the allinase enzyme resulting in the hydrolysis of non-proteinogenic amino acid S-allyl cysteine sulfoxide or known as (alliin) and mainly producing allicin [130].
Regarding allicin cytotoxicity, a study reported that the exposure to 12 µg/mL of allicin for 24 h, produced cytotoxic effect on MGC-803 and SGC-7901 cancer cells, including cellular membrane breakage [131]. While a study reported that allicin prevented proliferation of human mammary (MCF-7), endometrial (Ishikawa), and colon (HT-29) cancer cells at 50% inhibitory concentration equals to 10–25 μM [132]. Moreover, another study stated that when allicin used against MGC-803 and SGC-7901 cancer cells, the IC50 was 6.4 µg/mL, 7.3 µg/mL, respectively [131], while the LD50 of allicin was 120 mg/kg subcutaneous injection and 60 mg/kg intravenous injection in mice [133]. An in vivo study on bladder cancer has shown that allicin can delay the beginning of tumors following subcutaneous injection at a concentration of 12.5 mg and 25 mg [134].
Allicin has many activities, such as anti-oxidant [135] and antimicrobial [136]. Furthermore, it has a role in neuroinflammatory, and cardiovascular diseases [137], and an important role in combating cancer [138] due to its multiple mechanisms such as inducing apoptosis, inhibiting tumor growth, and preventing tumor angiogenesis [139]. For instant, 30 and 60 µg/mL of allicin induced apoptosis in U251 human glioma cells [140].
Many researchers had also studied the effects of allicin in combination therapies with other anti-cancer treatments including anti-cancer drugs and other plants. In one study, a mixture of allicin (ALN) and thymoquinone (TQ) has an excellent effect on anti-oxidant parameters in prostate and colon cancer cells [141]. Wamidh Talib reported that consumption of garlic (allicin rich extract) with lemon aqueous extract had decreased angiogenesis and induced apoptosis in breast cancer cells [142]. Moreover, Sarkhani et al. revealed that a mixture of allicin and methylsulfonylmethane had enhanced apoptosis because it increased the expression of caspase-3 mRNA expression in CD44± breast cancer cells [143].
On the other hand, allicin with antineoplastic drugs showed promising results. For example, allicin with cisplatin had shown many beneficial effects whether in fighting cancer or other helpful aspects. Pandey et al. demonstrated that using a low dose of allicin with cisplatin can potentiate the inhibitory activity of cisplatin and overcome the resistance of cisplatin. This is achieved by affecting hypoxia, which is known as a major mediator in cisplatin resistance, as allicin along with cisplatin had boosted the apoptosis in a ROS pathway in both normoxia and hypoxia [144]. Tigu et al. have reported that there was a synergistic effect against lung and colorectal cancer cells when allicin was used along with 5-FU [145]. Furthermore, allicin improved 5-FU resistance in gastric cancer cells by lowering the expression of Wnt Family Member 5A gene (WNT5A), CD44 receptor, MDR1, p-glycoprotein (p-gp) [146]. Fayin also reported that allicin had improved the apoptosis effect of 5-FU in MEC-1 cells [147]. Moreover, Xi et al. revealed that a mixture of allicin and Adriamycin had inhibited the proliferation and induced apoptosis in gastric cancer [148]. Additionally, allicin had improved the effectiveness of tamoxifen in the existence or lacking 17-b estradiol [149].
Moreover, Wu et al. revealed that allicin had protected the auditory hair cells, and spiral ganglion neurons from the apoptosis that is triggered by cisplatin [150], such result supports the fact that allicin can help in protecting from vestibular dysfunction [151]. In addition to this, a mixture of allicin and ascorbic acid alongside cisplatin displayed a neuroprotective effect against cisplatin due to allicin anti-oxidant and anti-inflammatory effects [152]. While with doxorubicin, allicin had improved the cardio-toxic effects of this anti-cancer drug by inhibiting oxidative stress, and inflammation [153]. Moreover, allicin with 5-FU had improved chemotherapy sensitivity in hepatic cancer cells due to induction of apoptosis by ROS-mediated mitochondrial pathways [154].

2.6. Thymoquinone

Thymoquinone (TQ) (2-Isopropyl-5-methylbenzo-1, 4-quinone) is a monoterpenoid compound [155] (Figure 6). It is extracted from the volatile and fixed oil of Nigella sativa (black seed) [156]. TQ is therapeutically active as an anti-microbial, anti-inflammatory, hypoglycemic, antiparasitic, antihypertensive, and anticancer agent [157].
TQ showed a significant antitumor effect on various types of cancer such as breast cancer [158], prostate cancer [159], gastric cancer [160], and bladder cancer [161]. Interestingly, TQ IC50 value was found to be 46 μM in a hepatocellular carcinoma cell line [162]. TQ is considered a safe natural product as its LD50 values for oral administration are 300–2400 mg/kg in mice and 250–794 mg/kg in rats [163]. While its therapeutic dose was about 10 mg/kg/intraperitoneally in mice [164].
Numerous studies demonstrated TQ anticancer mechanisms. Generally, it exerts its antitumor activity by modulating epigenetic machinery, altering gene expression of non-coding RNAs [165]. Moreover, via affecting several biological pathways that are implicated in apoptosis, proliferation, cell cycle regulation, and cancer metastasis [166]. In bladder cancer cell lines, 40 mmol/L of TQ stimulated apoptosis via ER-mediated mitochondrial apoptotic pathway [161].
TQ combination with various chemotherapeutic agents had enhanced the anticancer activity of them. For example, 46 μM TQ along with 64.5 μM resveratrol is considered a novel therapeutic strategy in the HCC cell line. Their combination resulted in significant cell inhibition and increased caspase-3 to induce apoptosis [162]. In an in vivo study, (20 mg·kg−1) of oral TQ improved the effectiveness of cisplatin in HCC treatment via controlling the GRP78/CHOP/caspase-3 pathway [167]. Furthermore, in breast cancer treatment, a combination of TQ and paclitaxel remarkably increased the rate of apoptotic/necrotic cell death in T47D cells, and induced autophagy in MCF-7 cells [168]. In vitro and in vivo models study reported that 10 μM TQ with 50 nM doxorubicin combination, enhanced cell death in adult T-cell leukemia. Thus, it increased ROS and resulted in disruption of the mitochondrial membrane [169]. A triple combination of (20 mg/kg) TQ, (15 mg/kg) pentoxifylline, and (7.5 mg/kg) cisplatin in mice, enhanced the chemotherapeutic activity of cisplatin by Notch pathway suppression [170]. A synergistic antitumor effect was detected between (10 mg/kg)TQ and (1 mg/kg) melatonin leading to minimizing the tumor size with a 60% percentage cure according to an in vivo study [171]. Similar to many chemotherapeutic agents, TQ can significantly enhance the effect of other natural products. TQ and royal jelly (RJ) together enhanced the anticancer activity of both against MDA-MB-231 breast cancer cells [172]. Moreover, in breast adenocarcinoma, a combination of (50 and 100 µM) TQ and (450 µM) ferulic acid required the use of lower doses of both to suppress the proliferation of cultured MDA-MB 231cells [173]. Additionally, TQ and quercetin potentiate apoptosis in NSCLC cell lines via the Bax/Bcl2 cascade [174]. A significant improvement in anticancer activity was examined when combined TQ with piperine (PIP) in EMT6/P cells injected in Balb/C mice. The combination treatment of (25 mg/kg/day of PIP and 10 mg/kg/day of TQ for 14 days) lead to a remarkable dropping in tumor size with a 60% of cure [175].

2.7. Piperine

It is most commonly found in the fruits and roots of Piper nigrum L. (black pepper) and Piper longum L. (long pepper) in the Piperaceae family as piperine (1-Piperoylpiperidine) [176] (Figure 7).
In vitro and in vivo anticancer effects of Piper nigrum extracts on colorectal cancer cells (HCT-116) and lung cancer cells (A549) were with IC50: HCT-116: 165 µM A549: 135 [177]. Another study by Gunasekaran et al. showed that IC50 was 75 µM (24 h) 30 µM (48 h) in Hepatocellular cancer [178]. Moreover, in leukemia IC50 was 25 µM (24 h) [179]. Regarding toxicity, after intravenous administration piperine LD50 was 15.1 mg per kg for adult mice [180]. In BALB/C mice implanted with mouse mammary EMT6/P cancer cells, the intraperitoneal treatment of piperine (25 mg/kg/day for 14 days) considerably reduced the tumor size [181]. In breast cancer, female BALB/C bearing 4T1 cell were treated with 2.5 or 5 mg/kg piperine every 3 days and tumor regression was reported [182]. Piperine inhibited lung metastasis of melanoma cells after its intraperitoneal injection at a concentration of 200 µmol/kg [183]. It also inhibits cell proliferation in prostate cancer cells implanted in nude mice at a therapeutic dose of 100 mg/kg/day (intraperitoneal) [184].
Piperine (PIP) activates apoptotic signaling cascades, inhibits cell proliferation, arrests the cell cycle, alters redox homeostasis, modulates ER stress and autophagy, inhibits angiogenesis, induces detoxification enzymes, and sensitizes tumors to radiotherapy and chemotherapy [185]. These mechanisms of action can help to prevent cancer. It can activate both intrinsic and extrinsic apoptotic pathways at the molecular level. Piperine suppressed mouse 4T1 breast tumor growth and metastasis [182]. Administration of piperine activated caspase 3-mediated intrinsic apoptosis in 4T1 cells and induced G2/M phase cell cycle arrest [182]. In another study, piperine reduced tumor growth in nude mice xenografted with androgen-dependent (PC3) and independent (LNCaP, DU145) prostate cancer cells [184]. It also inhibits prostate cancer cell growth by reducing phosphorylated STAT-3 and NF-B [184].
A variety of cell and tissue-specific and dose-dependent effects of piperine-mediated redox change cellular physiology. It can either enhance cell survival or commit the cell to death, depending on the situation. Oxidative stress-induced cell damage can be prevented by quenching ROS and other reactive metabolic intermediates, such as free radicals, with piperine [186,187]. A variety of protein regulators and checkpoints have been linked to the ability of piperine to halt the progression of cancer cells at various points in the cell cycle. Piperine in 100–200 µM concentration led to apoptosis and G1 phase cell cycle arrest in melanoma cells via activation of Checkpoint Kinase-1 [188].
In vitro, piperine demonstrates a synergistic anticancer effect when combined with paclitaxel on the MCF-7 cell line [189]. Another study indicates that combinations of piperine, hesperidin, and bee venom enhance the anti-cancer effects of tamoxifen in MCF7 and T47D cell lines [190]. In addition, the combination of piperine and doxorubicin inhibited tumor growth in BALB/C mice subcutaneously injected with MDA-MB-231 cells in vitro more effectively than either agent alone [191]. Piperine inhibits hepatic CYP3A4 activity in vivo, correlating with an increase in docetaxel’s AUC, half-life, and maximum plasma concentration. In addition, the synergistic administration of piperine and docetaxel significantly improved the antitumor efficacy of docetaxel in a castration-resistant human prostate cancer animal model [192]. Additionally, a study using in vitro and in vivo models, showed that the piperine and thymoquinone combination exerted a synergistic inhibition in breast cancer. This mainly was achieved by inhibition of angiogenesis, induction of apoptosis, and shifting toward T helper1 immune response [181].

2.8. Emodin

Emodin (EMD) is a natural anthraquinone derivative. Chemically it is (1,3,8-trihydroxy-6-methyl-anthraquinone) [193,194] (Figure 8). This phytochemical has been extracted from different Chinese medicinal herbs including Radix rhizoma Rhei, Aloe vera, Polygonum multiflorum, Giant knotweed, Rheum palmatum, and Polygonum cuspidatum [194,195,196]. Moreover, it can be found in the bark and roots of many other different plants, molds, and lichens [197].
Recently, emodin earned attention due to its diverse activity. It displays antibacterial [198], anti-inflammatory, antioxidant, antiallergic, antihypertensive, antidiabetic, neuroprotective, and hepatoprotective properties [199,200,201,202,203]. It may be used as a photosensitizing agent in photodynamic therapy [204]. In addition, it prevents immunosuppression and exhibits anticancer activity [205,206]. Emodin has shown its antitumor activity against colon cancer, breast cancer, non-small-cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, leukemia, and hepatocellular carcinoma (HCC) [207,208].
Narender et al. reported that emodin cytotoxicity was 3.5 μM in HepG2 cell line [209]. Regarding emodin toxicity, Luo tao et al. found that 100, 200 and 400 μM of emodin resulted in reproductive toxicity in humans when applied to ejaculated human sperm [107], whereas its therapeutic dose in athymic nude mice injected with MDA-MB-231 breast cancer cells was 40 mg/kg after intraperitoneal injection [210].
Emodin displays its anticancer effect on different cell lines with different mechanisms. Generally, emodin exerts its anti-tumor activity by inducing mitochondrial apoptosis and inhibiting pathways that promote proliferation, inflammation, angiogenesis, and tumorigenesis [211]. In colon cancer (CC), emodin regulated the localization and expression of Bcl-2 family proteins by regulating PI3K/AKT, MAPK/JNK, STAT, and NF-κβ molecular signaling pathways [212]. Moreover, it inhibited the migration and invasion of CC cells by downregulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway [213]. More interestingly, treatment with emodin led to mitochondrial dysfunction, reactive oxygen species accumulation, and induced apoptosis in (CC) cells via induction of autophagy [214]. Furthermore, in HCT116 human (CC) cells, 10–50 µM emodin-induced apoptosis inhibited proliferation, suppressed the expression of fatty acid synthase (FASN), inhibited intracellular FASN activity, and fatty acid biogenesis. Needless to say, (FASN) is an important factor in the development of colon carcinoma [215].
Interestingly, emodin’s benefits are not limited to natural products alone, but again, it can improve the anticancer effect of several chemotherapeutic agents. Emodin’s combination with sorafenib resulted in improving the anti-cancer effect of sorafenib in HCC cells. Furthermore, this combination synergistically increased apoptotic cells and cell cycle arrest in the G1 phase using concentrations of 20 μM emodin and 2 μM sorafenib [207]. Moreover, a combination with EGFR inhibitor afatinib resulted in a higher rate of inhibiting cell proliferation in pancreatic cancer in concentrations ranging between 30, 60 and 90 μM of emodin [216]. Furthermore, the inhibition of the growth effect of cisplatin was remarkably improved by emodin in lung adenocarcinoma A549/DDP cells [217]. In addition, in endometrial cancer cells, emodin and cisplatin combination inhibited the expression of drug-resistant genes by decreasing the reactive oxygen species (ROS) levels. Consequently, resulting in increasing chemosensitivity [218]. Shuai Peng et al. demonstrated that emodin (5 µM) enhanced H460 and A549 cell sensitivity to cisplatin through P-glycoprotein downregulation in non-small cell lung cancer (NSCLC) [219]. More and more, emodin with a concentration between (5, 10, 20, and 40 μM) enhanced the anticancer effect of paclitaxel by inhibiting the proliferation of A549 cells in NSCLC [212]. In pancreatic cancer, emodin (40 μM) inhibited IKKβ/NF-κB signaling pathway and reverses gemcitabine resistance [213]. Generally, a combination of natural products has shown promising results in treating disease, either as synergistic or as an additive effect [5]. In breast cancer, a combination of emodin (10 μM) and berberine (10 and 5 μM) synergistically repealed the SIK3/mTOR pathway. As a result, the aerobic glycolysis and cell growth were suppressed leading eventually to inducing apoptosis [220].

2.9. Parthenolide

Parthenolide (PTL) is a germacrene sesquiterpene lactone [215]. Chemically, it consists of an α-methylene-γ-lactone ring and epoxide group, which are responsible for interacting with nucleophilic sites of biological molecules [221] (Figure 9). PTL is extracted from different plants of the Asteraceae family [222] and is the main constituent of the feverfew medicinal plant, Tanacetum parthenium [223]. Generally, it possesses diverse biological activity extending from antibacterial, anti-inflammatory, and phytotoxic to antitumor activity [224].
PTL IC50 values were 9.54 and 8.42 μM against MCF-7 and SiHa cells, respectively [225]. Regarding to a study, PTL showed LD50 at 200 mg/kg, when administered orally [226]. On the other hand, 10 mg·kg−1·day−1 of PTL administered intraperitoneally, was therapeutically effective as anticancer agent in mice injected with U87MG cells [227].
PTL has been reported as an anticancer agent using different mechanisms. Mostly, by inhibiting the nuclear transcription factor-kappa (NF-κB) signaling pathway and cell growth [221]. Add to that its ability to induce apoptosis and G0/G1 cell cycle arrest [223]. PTL stimulated apoptosis in 50–200 µmol/L concentration in human uveal melanoma cells [228]. Therefore, it is active against different types of cancer including colorectal cancer [222], breast cancer [229], and lung cancer [230].
A PTL (9 and 15 µM) combination with Epirubicin (EPR) (2.5 and 3.5 µM), which is an anthracycline doxorubicin analog, led to improving cytotoxicity and apoptosis in MDA-MB-468 breast cancer cells. Thus, the dose of EPR could be reduced and the undesirable side effects will be preventable [221].
Furthermore, in vitro study considered PTL as a potent agent at a concentration of 1 μg/mL, as it enhanced the effectiveness of arsenic trioxide (2 µM) in the treatment of adult T-cell leukemia/lymphoma [231]. Se-lim Kim et al. demonstrated that PTL 10 μM combination with balsalazide improved the anticancer activity via blocking NF-κB activation and therefore prevented colon carcinogenesis from long-lasting inflammation [221]. In addition, PTL sensitized colorectal cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand. That was achieved by increasing the surface expression of death receptor 5 proteins, upregulating the expression of proteins elaborate in the mitochondrial apoptotic pathway, and lastly increasing caspase activation [223]. Se-lim Kim et al. demonstrated that using (5 or 10 μmol/L) PTL combination with 20 mmol/L balsalazide in vitro and in vivo improved the anticancer activity via blocking NF-κB activation. Therefore preventing colon carcinogenesis from long-lasting inflammation [232]. Recently, a combination of natural products is of interest, because they are safe, inexpensive, and effective. For instance, PTL (1.5 μg/mL) and different concentrations of ginsenoside compound K have acted synergistically as antineoplastic agents with minimizing adverse effects both in vitro and in vivo [233]. Once more, an interesting in vitro and in vivo study showed that a cocktail combination of PTL, betulinic acid, honokiol, and ginsenoside Rh2 displayed a synergistic activity in liposome systems for lung cancer treatment [234].

2.10. Luteolin

Luteolin (LTN) (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone) [235] (Figure 10) is a flavonoid that can be found in fruits and vegetables, such as parsley, sweet bell peppers, celery, onion leaves, chrysanthemum flowers, carrots, and broccoli [229]. Several studies have shown that LTN owns diverse biological activities. For instance, it acts as a neuroprotective [236], anti-diabetic, antioxidant, anti-microbial, anti-allergic, anti-inflammatory, chemopreventive, and chemotherapeutic agent [237].
Seo et al. demonstrated that LTN IC50 was 9.8 μM against PC-3 prostate cancer cell lines [238]. According to a study, luteolin LD50 was 150 mg/kg when delivered through nasogastric intubation in rats [239]. While 40 mg/kg of LTN was able to suppress the Nrf2 signaling pathway and cancer development in vivo [240]. Luteolin displays its antineoplastic activity in the forms of diverse mechanisms including hampering the activity of epigenetic targets, such as DNA methyltransferases [241], inducing autophagy, cell apoptosis, and inhibit migration and invasion [242]. A study demonstrated that 10–30 µM of LTN stimulated apoptosis and autophagy in glioma [243].
Interestingly, luteolin showed a synergistic anticancer effect with 5-fluorouracil on HepG2 and Bel7402 cells in human hepatocellular carcinoma. This effect was achieved using various dose ratios (luteolin:5-fluorouracil = 10:1, 20:1, 40:1) [244]. In drug-resistant ovarian cancer, 10, 50, and 100 μM of LTN significantly sensitized the antineoplastic effect of 2 μg/mL cisplatin. Thus initiating apoptosis and inhibiting cell invasion and migration both in vitro and in vivo [245].
A study revealed that a combination of luteolin and quercetin in (50–1000 mg/mL) concentration, synergistically improved the antitumor effect of 5-Fluorouracil (5-FU) in HT 29 cells. Consequently, it minimizes the unwanted toxic effects of 5-FU in colorectal cancer treatment [246]. Furthermore, in vitro study reported that 10 and 20 μM luteolin and 20 and 40 μM quercetin inhibited the invasion and migration of squamous carcinoma decreasing Src/Stat3/S100A7 signaling [247]. Moreover, (10, 20, and 40 μM) of luteolin and quercetin together caused a reduction in ubiquitin E2S expression led eventually to metastatic inhibition of A431-III cervical cancer cells [248]. Furthermore, when 100 or 140 mg/mL of luteolin was combined with hesperidin, an enhancement in their anticancer activity was achieved. That is due to the declining cell viability and suppression of cell cycle progression in MCF-7 cells [249]. Similarly, 20 µM luteolin and 50 µM silibinin worked synergistically together, especially in preventing cell proliferation, migration, and invasion in human glioblastoma SNB19 and GSC cells, as well as in the drug-resistant glioblastoma stem cells [250].

2.11. Quercetin

Quercetin (QUR) is one of the most well know flavonoids that are found in many types of fruits and vegetables; it is a flavonol that is one of the six types of flavonoids (Figure 11). Quercetin is aglycone in nature thus mainly it is not soluble in cold water, poorly soluble in hot water, and fairly soluble in lipids and alcohol as a result it is mainly attached to a glycosyl group using sugar as glucose, rhamnose, or rutinose to improve the quercetin solubility [251].
According to its cytotoxicity, a study stated that the IC50 of quercetin was 30 μM, which was calculated in vitro by the MTT colorimetric assay [252]. Quercetin LD50 was 97 mg/kg when administered subcutaneously, while its LD50 after intravenous administration was about 18 mg/kg in a mouse model [28]. When quercetin used in vivo at concentration of 100 and 200 mg/kg in mice bearing CT-26 and MCF-7 tumors, it showed significant higher survival rate compared to control [253]. Another study reported that administration of 10 mg/kg of quercetin intraperitoneally had inhibited cell proliferation in HepG2 tumor-bearing BALB/C/nu mice [254].
Quercetin has been utilized in different areas due to its different mechanisms such as antioxidant [241], antimicrobial [242], and anti-inflammatory [255]. It also has a great role in cancer, as it controls many factors in the cancer activity such as apoptotic proteins, cell cycle, and angiogenesis [256]. As an example, 25, 50 µM of quercetin induced apoptosis and DNA fragmentation in HeLa cervical cancer cells [257]. For these reasons, many researchers studied the final effects when quercetin had used with natural products and other anti-cancer drugs. Quercetin works synergistically with curcumin in the triple-negative breast cancer cell line by altering the BRCA1 deficiency and therefore augmenting the activity of anti-cancer drugs [258]. Moreover, quercetin and curcumin enhanced the apoptotic effect of K562 cells in chronic myeloid leukemia due to the increase in ROS and impairment of the mitochondrial membrane potential [259]. Using resveratrol with quercitin can cause DNA injury, cell growth inhibition, stimulation of apoptosis in oral cancer cell lines. It promoted apotosis via downregulation of Histone deacetylase (HDAC)1, HDAC3, and HDAC8 [260]. Moreover, a promising nanostructured lipid carrier (NLC) gel of quercetin and resveratrol had shown an improvement in the deposition of these two drugs to the epidermal layer in skin cancer cells [261]. Furthermore, combining thymoquinone with quercitin enriched the apoptosis in non-small lung cancer cell lines due to the modulation of anti-apoptotic protein Bcl2 and the initiation of proapoptotic Bax [174]. In addition, it was found that using luteolin with quercitin can prevent the invasion of cervical cancer cells as a result of a lowering in ubiquitin E2S ligase (UBE2S) [248]. With chemotherapy, quercetin potentiates the effect of cisplatin in cervical cancer cells due to the induction of apoptosis as a result of declining Matrix Metallopeptidase 2 (MMP2), Methyltransferase 3, N6-Adenosine-Methyltransferase Complex Catalytic Subunit (METTL3), P-Gp and ezrin production [262]. Using quercetin with 5-FU increased the sensitivity of MCF-7 breast cancer cells toward 5-FU [263]. On the other hand, combining quercetin with tamoxifen improved its effect on resistant breast cancer cells [264]. Moreover, quercetin had improved doxorubicin’s accumulation in breast cancer cells by downregulating the expression of efflux receptors, including breast Cancer Resistant Protein (BCRP), P-gp, and multidrug resistance protein 1 (MRP). It also lowered the side effects of doxorubicin [265]. In addition, nano-querectin had improved the cytotoxicity of doxorubicin in MCF-7 breast cancer cells [266]. Fang et al. reported that mesoporous silica nano-particles loaded with quercetin had improved the efficacy of doxorubicin treatment in gastric cancer cell lines [267]. In hepatocellular carcinoma (HCC), quercetin potentiated the growth suppression effect of cisplatin in HepG2 cells [268]. In addition, Zhu et al. reported that quercetin potentiates the effect of vincristine when delivered as nanocarriers in lymphoma in vitro and in vivo model [269]. It is worth mentioning that adding quercetin with paclitaxel therapy has improved the anticancer effect in prostate cancer both in vitro and in vivo, through triggering ROS production, induction of apoptosis, preventing cell migration and stimulating cell arrest in the G2/M phase [270]. Moreover, QUR and paclitaxel had enhanced the multi-drug resistance in breast cancer MCF-7/ADR cell lines and in vivo by decreasing P-gp expression and inhibiting of the cellular paclitaxel reflux [271]. In addition, Huang et al. revealed that nanoparticles loaded with quercetin had improved tumor targeting and radiotherapy treatment in 4T1 cells and in mice [272]. In combination with other chemo-drug, Li et al. reported that using quercetin with cisplatin had improved the apoptosis in oral squamous cell carcinoma (OSCC) cell lines and mice. This is due to the inhibition of NF-κB thus downregulating of X-linked inhibitor of apoptosis protein (xIAP) [273]. Furthermore, it increased the growth inhibition of cisplatin in breast cancer in mice [274]. Additionally, Gonzalezet et al. revealed that quercetin had improved the nephrotoxicity that accompanied cisplatin in rats [275]. Moreover, it improved oral mucositis which is induced by 5-FU in mice [263]. In addition, it offered protection to damaged peripheral nerves associated with vincristine use due to quercetin’s role in decreasing the oxidative stress, inflammation, stress and neuronal cell damage in rats [269].

2.12. Anthocyanins

Anthocyanins (ACN) are water-soluble flavonoids seen as pigments in the dark color of fruits and vegetables such as berries, pomegranates, berries, and rice [276]. They give different colors depending on their pH, they may appear red, purple, blue, or black. Their fundamental structural part is 2-phenylchromenylium (flavylium) [277] (Figure 12).
They are active in a variety of health conditions such as cardiovascular [278], neurological [279], and metabolic diseases [280]. Moreover, anthocyanins have an active role in cancer management due to their basic specification as anti-oxidants, anti-inflammatory, anti-invasion, and anti-metastatic [281].
A study revealed that 146–2199 mg/100 g of anthocyanin exerted a good antioxidant as well as anticancer activity [282]. Based on numerous studies, anthocyanins toxicity is considered low. For instance, a study revealed no significant effect upon 90 days intake of 0–1000 mg/kg/day anthocyanin in ovariectomized rats [283]. Furthermore, animal studies had not recognized any lethal effects regarding anthocyanins (from blueberries, currants, and/or elderberries). Moreover, the IC50 value for anthocyanin at 24 h after treating DU-145 cells was 60–90 µM [284]. In this context, the LD50 values for highly purified extract of Vaccinium myrtillus berries containing 36% anthocyanosides were over 2000 mg/kg in mouse and in rats without any toxic symptoms [285]. Moreover, in BALB/C nude mice bearing ErbB2 positive breast cancer, the oral administration of black rice anthocyanins (150 mg/kg/day) decreased transplanted tumor development, hindered pulmonary metastasis, and reduced lung tumor nodules [286].
Due to the valuable activity of the anthocyanins, many researchers investigated the outcomes when they are combined with other anti-cancer therapies including drugs and natural products. For instance, Yin et al. reported that cyanidin 3 glucoside chloride acts along with luteolin by increasing apoptosis and inhibiting the proliferation of breast and colon cancer cell lines [287]. Regarding combining anthocyanins with other chemotheraputic agents, Li et al. revealed that a combination of 5-FU and 50 μg/mL blackberries anthocyanins decreased the proliferation and migration of SW480 cells in colorectal cancer [288]. Paramanantham et al. stated that 400 µg/mL of anthocyanins isolated from Coignetiae pulliat had advanced the sensitivity of cisplatin in MCF-7 breast cancer cells resulting from the impairment of Akt and NF-κB activation [289]. Furthermore, an anthocyanin called cyanidin had been noticed to decrease the cardiotoxicity that is associated with cisplatin in 40–80 µM doses through preventing ROS-mediated apoptosis in H9c2 cells [290]. Pepe et al. also reported the cardio-protective effect of Citrus sinensis and Vitis vinifera anthocyanins with doxorubicin in vitro at a range between 1–25 µg/mL [291]. In addition, anthocyanins extracted from Oryza sativa L. and 5-FU improved the oral mucositis in vitro and in vivo using 500 mg/kg and 1000 mg/kg concentrations. This is by the activation of Nuclear Factor-κB which resulted in anti-inflammatory effects [292]. Anthocyanin from purple sweet potato had decreased doxorubicin cardiac toxicity using different concentrations (100, 200, and 400 μg/mL) according to in vitro and in vivo study. The previously mentioned effect was due to the decrease in inflammatory factors, such as nitric oxide and TNF-α, also due to the decline in creatine kinase, trimethylamine oxide, and lactic dehydrogenase triggered by myocardial damage [293]. Moreover, with 20 μg/mL trastuzumab, 1 μg/mL anthocyanins cyanidin 3 glucoside proved to show a synergistic effect in vitro and in vivo. As it had been noticed to decrease human epidermal growth factor receptor 2 (HER2) and improved the trastuzumab apoptotic effect in HER2-positive breast cancer [294]. Moreover, using 0.003–50 µM in a 100 µL of cyanidin 3 glucoside has shown to overcome trastuzumab-resistant in breast cancer cell line and mice xenograft model. The previous activity was due to decreasing the HER2, AKT, and MAPK activities [295]. Furthermore, Qi et al. had noticed that (200 and 400 mg/kg) anthocyanin from the fruits of Panax ginseng had improved the nephrotoxicity in mice, which is associated with cisplatin usage due to their anti-inflammatory and anti-oxidant influences [296]. Moreover, Gomes et al. reported the same nephroprotective effect with blackberries juice anthocyanins in mice but with a 10 mL/kg concentration [297]. Furthermore, Shi et al. had shown that the blueberry anthocyanins in a dose of 20 and 80 mg/kg/day for 7 days, had improved the liver damage in rats. Generally, liver damage is associated with cyclophosphamide usage due to the reduction of inflammation and apoptosis [298].

3. Conclusions

A combination of plant-derived natural products with other anti-cancer therapies showed a significant improvement in cancer management. Higher efficiency and lower toxicity were reported when combining these natural products with standard anticancer agents or other natural products. Curcumin, thymoquinone, and quercetin were extensively tested in combination anticancer therapies. Other plant-derived natural products were less tested. This could be due to several factors including: availability of the natural product, solubility, lack of clear mechanisms of action, and the cost of purchasing some natural products. Breast cancer was the most studied cancer in combination therapies in vivo and in vitro. Due to the limitation of current anti-cancer treatments such as toxicity, low solubility, low bioavailability, and resistance, combinations based on natural products is a promising strategy to develop more effective and less toxic treatments. Further studies are needed to design effective combinations of natural products that can augment conventional treatments. More studies are also needed to test complex combinations containing more than 2 natural products. Furthermore, the spectrum of activity of these combinations should be further expanded as many of the products were tested on limited cancer types. Figure 13 summarizes the main combination therapy of the natural compounds with other plant-derived compounds as well as chemotherapies. Table 1 shows the tested combination experimental design of natural compounds with other natural products and the outcomes of these studies. Table 2 demonstrates the main studies that included natural compounds in combination with chemotherapy.

Author Contributions

Conceptualization W.H.T.; methodology, D.A, R.A.H., A.I.M., A.O.A. and I.H.A.-Y.; software, A.I.M.; validation, W.H.T.; formal analysis, D.A., R.A.H., A.I.M., A.O.A. and I.H.A.-Y.; investigation, D.A., R.A.H., A.O.A.; resources, W.H.T.; data curation, I.H.A.-Y.; writing—original draft preparation, D.A., R.A.H., A.O.A.; writing—review and editing, W.H.T. and A.I.M.; visualization, A.I.M.; supervision, W.H.T.; project administration, W.H.T.; funding acquisition, W.H.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Applied Science Private University, Amman, Jordan, grant number [Grant No. DRGS-2020-2021-4].

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 23 July 2022).
  2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  3. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 2017, 7, 339–348. [Google Scholar] [CrossRef] [PubMed]
  4. Hauner, K.; Maisch, P.; Retz, M. Side effects of chemotherapy. Der Urologe. Ausg. A 2017, 56, 472–479. [Google Scholar] [CrossRef] [PubMed]
  5. Sauter, E.R. Cancer prevention and treatment using combination therapy with natural compounds. Expert Rev. Clin. Pharmacol. 2020, 13, 265–285. [Google Scholar] [CrossRef] [PubMed]
  6. Carvalho, F.S.; Burgeiro, A.; Garcia, R.; Moreno, A.J.; Carvalho, R.A.; Oliveira, P.J. Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy. Med. Res. Rev. 2014, 34, 106–135. [Google Scholar] [CrossRef]
  7. Nonnekens, J.; Hoeijmakers, J.H. After surviving cancer, what about late life effects of the cure? EMBO Mol. Med. 2017, 9, 4–6. [Google Scholar] [CrossRef]
  8. Wigmore, P.M.; Mustafa, S.; El-Beltagy, M.; Lyons, L.; Umka, J.; Bennett, G. Effects of 5-FU. Adv. Exp. Med. Biol. 2010, 678, 157–164. [Google Scholar] [CrossRef]
  9. Cragg, G.M.; Pezzuto, J.M. Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. Med. Princ. Pract. 2016, 25 (Suppl. 2), 41–59. [Google Scholar] [CrossRef]
  10. Talib, W.H.; Alsalahat, I.; Daoud, S. Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation. Molecules 2020, 25, 5319. [Google Scholar] [CrossRef]
  11. Irshad, R.; Husain, M. Natural products in the reprogramming of cancer epigenetics. Toxicol. Appl. Pharmacol. 2021, 417, 115467. [Google Scholar] [CrossRef]
  12. Talib, W.H.; Alsayed, A.R.; Barakat, M.; Abu-Taha, M.I.; Mahmod, A.I. Targeting Drug Chemo-Resistance in Cancer Using Natural Products. Biomedicines 2021, 9, 1353. [Google Scholar] [CrossRef]
  13. Dasari, S.; Njiki, S.; Mbemi, A.; Yedjou, C.G.; Tchounwou, P.B. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int. J. Mol. Sci. 2022, 23, 1532. [Google Scholar] [CrossRef]
  14. Bode, A.M.; Dong, Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev. Res. 2009, 2, 514–517. [Google Scholar] [CrossRef]
  15. Mokhtari, R.B.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022. [Google Scholar] [CrossRef]
  16. Nikanjam, M.; Liu, S.; Yang, J.; Kurzrock, R. Dosing three-drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients. Oncologist 2017, 22, 576–584. [Google Scholar] [CrossRef]
  17. Fantini, M.; Benvenuto, M.; Masuelli, L.; Frajese, G.V.; Tresoldi, I.; Modesti, A.; Bei, R. In Vitro and in Vivo Antitumoral Effects of Combinations of Polyphenols, or Polyphenols and Anticancer Drugs: Perspectives on Cancer Treatment. Int. J. Mol. Sci. 2015, 16, 9236. [Google Scholar] [CrossRef]
  18. Rizeq, B.; Gupta, I.; Ilesanmi, J.; AlSafran, M.; Rahman, M.M.; Ouhtit, A. The Power of Phytochemicals Combination in Cancer Chemoprevention. J. Cancer 2020, 11, 4521–4533. [Google Scholar] [CrossRef]
  19. Alibeiki, F.; Jafari, N.; Karimi, M.; Peeri Dogaheh, H. Potent anti-cancer effects of less polar Curcumin analogues on gastric adenocarcinoma and esophageal squamous cell carcinoma cells. Sci. Rep. 2017, 7, 2559. [Google Scholar] [CrossRef]
  20. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as “Curecumin”: From kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787–809. [Google Scholar] [CrossRef]
  21. Pawar, H.; Karde, M.; Mundle, N.; Jadhav, P.; Mehra, K.J.M.C. Phytochemical evaluation and curcumin content determination of turmeric rhizomes collected from Bhandara District of Maharashtra (India). Med. Chem. 2014, 4, 588–591. [Google Scholar] [CrossRef] [Green Version]
  22. Gupta, S.C.; Patchva, S.; Koh, W.; Aggarwal, B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol. 2012, 39, 283–299. [Google Scholar] [CrossRef] [PubMed]
  23. Rodrigues, F.C.; Kumar, N.A.; Thakur, G. Developments in the anticancer activity of structurally modified curcumin: An up-to-date review. Eur. J. Med. Chem. 2019, 177, 76–104. [Google Scholar] [CrossRef] [PubMed]
  24. Nagahama, K.; Utsumi, T.; Kumano, T.; Maekawa, S.; Oyama, N.; Kawakami, J. Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. Sci. Rep. 2016, 6, 30962. [Google Scholar] [CrossRef] [PubMed]
  25. Mirakabad, F.S.T.; Akbarzadeh, A.; Milani, M.; Zarghami, N.; Taheri-Anganeh, M.; Zeighamian, V.; Badrzadeh, F.; Rahmati-Yamchi, M. A Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif. Cells Nanomed. Biotechnol. 2016, 44, 423–430. [Google Scholar] [CrossRef]
  26. Yang, X.; Li, Z.; Wang, N.; Li, L.; Song, L.; He, T.; Sun, L.; Wang, Z.; Wu, Q.; Luo, N.J.S.r. Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Sci. Rep. 2015, 5, 10322. [Google Scholar] [CrossRef]
  27. Sadeghzadeh, H.; Pilehvar-Soltanahmadi, Y.; Akbarzadeh, A.; Dariushnejad, H.; Sanjarian, F.; Zarghami, N.J.A.-C.A.i.M.C. The effects of nanoencapsulated curcumin-Fe3O4 on proliferation and hTERT gene expression in lung cancer cells. Anti-Cancer Agents Med. Chem. 2017, 17, 1363–1373. [Google Scholar] [CrossRef]
  28. Sax, N.I.; Lewis, R.J. Dangerous Properties of Industrial Materials; Van Nostrand Reinhold: New York, NY, USA, 1989; Volume 3. [Google Scholar]
  29. Harishkumar, R.; Reddy, L.P.K.; Karadkar, S.H.; Al Murad, M.; Karthik, S.S.; Manigandan, S.; Selvaraj, C.I.; Christopher, J.G. Toxicity and selective biochemical assessment of quercetin, gallic acid, and curcumin in zebrafish. Biol. Pharm. Bull. 2019, 42, 1969–1976. [Google Scholar] [CrossRef]
  30. Fetoni, A.R.; Eramo, S.L.; Paciello, F.; Rolesi, R.; Podda, M.V.; Troiani, D.; Paludetti, G. Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction. Otol. Neurotol. 2014, 35, e169–e177. [Google Scholar] [CrossRef]
  31. Panahi, Y.; Saadat, A.; Beiraghdar, F.; Sahebkar, A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytother. Res. 2014, 28, 1461–1467. [Google Scholar] [CrossRef]
  32. Kunnumakkara, A.B.; Bordoloi, D.; Padmavathi, G.; Monisha, J.; Roy, N.K.; Prasad, S.; Aggarwal, B.B. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br. J. Pharmacol. 2017, 174, 1325–1348. [Google Scholar] [CrossRef] [Green Version]
  33. Kuttikrishnan, S.; Siveen, K.S.; Prabhu, K.S.; Khan, A.Q.; Ahmed, E.I.; Akhtar, S.; Ali, T.A.; Merhi, M.; Dermime, S.; Steinhoff, M. Curcumin induces apoptotic cell death via inhibition of PI3-kinase/AKT pathway in B-precursor acute lymphoblastic leukemia. Front. Oncol. 2019, 9, 484. [Google Scholar] [CrossRef]
  34. Kang, Y.; Hu, W.; Bai, E.; Zheng, H.; Liu, Z.; Wu, J.; Jin, R.; Zhao, C.; Liang, G. Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathway. Onco Targets Ther. 2016, 9, 7373. [Google Scholar] [CrossRef]
  35. Bava, S.V.; Puliappadamba, V.T.; Deepti, A.; Nair, A.; Karunagaran, D.; Anto, R.J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J. Biol. Chem. 2005, 280, 6301–6308. [Google Scholar] [CrossRef]
  36. Punfa, W.; Suzuki, S.; Pitchakarn, P.; Yodkeeree, S.; Naiki, T.; Takahashi, S.; Limtrakul, P. Curcumin-loaded PLGA nanoparticles conjugated with anti-P-glycoprotein antibody to overcome multidrug resistance. Asian Pac. J. Cancer Prev. 2014, 15, 9249–9258. [Google Scholar] [CrossRef]
  37. Dang, Y.-P.; Yuan, X.-Y.; Tian, R.; Li, D.-G.; Liu, W. Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-κB-p53-caspase-3 pathway. Exp. Ther. Med. 2015, 9, 1470–1476. [Google Scholar] [CrossRef]
  38. Banerjee, S.; Singh, S.K.; Chowdhury, I.; Lillard, J.W., Jr.; Singh, R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front. Biosci. 2017, 9, 235. [Google Scholar]
  39. Lindsay, C.; Kostiuk, M.; Conrad, D.; O’Connell, D.A.; Harris, J.; Seikaly, H.; Biron, V.L. Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells. Mol. Carcinog. 2019, 58, 1946–1959. [Google Scholar] [CrossRef]
  40. Eslami, S.S.; Jafari, D.; Montazeri, H.; Sadeghizadeh, M.; Tarighi, P. Combination of Curcumin and Metformin Inhibits Cell Growth and Induces Apoptosis without Affecting the Cell Cycle in LNCaP Prostate Cancer Cell Line. Nutr. Cancer 2021, 73, 1026–1039. [Google Scholar] [CrossRef]
  41. Soheilifar, M.H.; Moshtaghian, A.; Maadi, H.; Izadi, F.; Saidijam, M. BMI1 Roles in Cancer Stem Cells and Its Association with MicroRNAs Dysregulation in Cancer: Emphasis on Colorectal Cancer. Int. J. Cancer Manag. 2018, 11, e82926. [Google Scholar] [CrossRef]
  42. Shakibaei, M.; Buhrmann, C.; Kraehe, P.; Shayan, P.; Lueders, C.; Goel, A. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS ONE 2014, 9, e85397. [Google Scholar]
  43. Shemesh, N.; Arber, N. Curcumin alone and in combination for prevention of colorectal cancer. Curr. Color. Cancer Rep. 2014, 10, 62–67. [Google Scholar] [CrossRef]
  44. Zhu, X.; Shen, H.; Yin, X.; Long, L.; Xie, C.; Liu, Y.; Hui, L.; Lin, X.; Fang, Y.; Cao, Y.; et al. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 2016, 35, 323–332. [Google Scholar] [CrossRef] [PubMed]
  45. Guorgui, J.; Wang, R.; Mattheolabakis, G.; Mackenzie, G.G. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice. Arch. Biochem. Biophys. 2018, 648, 12–19. [Google Scholar] [CrossRef] [PubMed]
  46. Hu, Y.; Ran, M.; Wang, B.; Lin, Y.; Cheng, Y.; Zheng, S. Co-delivery of docetaxel and curcumin via nanomicelles for enhancing anti-ovarian cancer treatment. Int. J. Nanomed. 2020, 15, 9703. [Google Scholar] [CrossRef]
  47. Toden, S.; Okugawa, Y.; Buhrmann, C.; Nattamai, D.; Anguiano, E.; Baldwin, N.; Shakibaei, M.; Boland, C.R.; Goel, A. Novel evidence for curcumin and boswellic acid–induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prev. Res. 2015, 8, 431–443. [Google Scholar] [CrossRef]
  48. Ide, H.; Tokiwa, S.; Sakamaki, K.; Nishio, K.; Isotani, S.; Muto, S.; Hama, T.; Masuda, H.; Horie, S. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010, 70, 1127–1133. [Google Scholar] [CrossRef]
  49. Arena, A.; Romeo, M.A.; Benedetti, R.; Masuelli, L.; Bei, R.; Gilardini Montani, M.S.; Cirone, M. New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects. Pharmaceuticals 2021, 14, 1068. [Google Scholar] [CrossRef]
  50. Piwowarczyk, L.; Stawny, M.; Mlynarczyk, D.T.; Muszalska-Kolos, I.; Goslinski, T.; Jelińska, A. Role of Curcumin and (−)-Epigallocatechin-3-O-Gallate in Bladder Cancer Treatment: A Review. Cancers 2020, 12, 1801. [Google Scholar] [CrossRef]
  51. Ahn, J.-C.; Biswas, R.; Kim, J.-S. The enhanced apoptotic effect of photodynamic therapy using photofrin combined with genistein in human ovarian cancer cell SK-OV-3. Biomed. Res. 2014, 25, 51–57. [Google Scholar]
  52. Gianfredi, V.; Nucci, D.; Vannini, S.; Villarini, M.; Moretti, M. In vitro biological effects of sulforaphane (SFN), epigallocatechin-3-gallate (EGCG), and curcumin on breast cancer cells: A systematic review of the literature. Nutr. Cancer 2017, 69, 969–978. [Google Scholar] [CrossRef]
  53. Mokbel, K.; Wazir, U.; Mokbel, K. Chemoprevention of prostate cancer by natural agents: Evidence from molecular and epidemiological studies. Anticancer. Res. 2019, 39, 5231–5259. [Google Scholar] [CrossRef]
  54. Somers-Edgar, T.J.; Scandlyn, M.J.; Stuart, E.C.; Le Nedelec, M.J.; Valentine, S.P.; Rosengren, R.J. The combination of epigallocatechin gallate and curcumin suppresses ERα-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 2008, 122, 1966–1971. [Google Scholar] [CrossRef]
  55. Guo, J.; Li, W.; Shi, H.; Xie, X.; Li, L.; Tang, H.; Wu, M.; Kong, Y.; Yang, L.; Gao, J.; et al. Correction to: Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol. Cell. Biochem. 2022, 477, 979–980. [Google Scholar] [CrossRef]
  56. El-Far, A.H.; Saddiq, A.A.; Mohamed, S.A.; Almaghrabi, O.A.; Mousa, S.A. Curcumin and Thymoquinone Combination Attenuates Breast Cancer Cell Lines’ Progression. Integr. Cancer Ther. 2022, 21, 15347354221099537. [Google Scholar] [CrossRef]
  57. Xiong, H.Q.; Abbruzzese, J.L.; Lin, E.; Wang, L.; Zheng, L.; Xie, K. NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int. J. Cancer 2004, 108, 181–188. [Google Scholar] [CrossRef]
  58. Kunnumakkara, A.B.; Guha, S.; Krishnan, S.; Diagaradjane, P.; Gelovani, J.; Aggarwal, B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB–regulated gene products. Cancer Res. 2007, 67, 3853–3861. [Google Scholar] [CrossRef]
  59. Bartik, L.; Whitfield, G.K.; Kaczmarska, M.; Lowmiller, C.L.; Moffet, E.W.; Furmick, J.K.; Hernandez, Z.; Haussler, C.A.; Haussler, M.R.; Jurutka, P.W. Curcumin: A novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J. Nutr. Biochem. 2010, 21, 1153–1161. [Google Scholar] [CrossRef]
  60. Srivastava, N.S.; Srivastava, R.A.K. Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells. Phytomedicine 2019, 52, 117–128. [Google Scholar] [CrossRef]
  61. Kollár, P.; Hotolová, H. Biological effects of resveratrol and other constituents of wine. Ceska Slov. Farm. 2003, 52, 272–281. [Google Scholar]
  62. Catalgol, B.; Batirel, S.; Taga, Y.; Ozer, N.K. Resveratrol: French paradox revisited. Front. Pharmacol. 2012, 3, 141. [Google Scholar] [CrossRef]
  63. Almeida, L.; Vaz-da-Silva, M.; Falcão, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L.; et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53, S7–S15. [Google Scholar] [CrossRef]
  64. A Kroon, P.; Iyer, A.; Chunduri, P.; Chan, V.; Brown, L. The cardiovascular nutrapharmacology of resveratrol: Pharmacokinetics, molecular mechanisms and therapeutic potential. Curr. Med. Chem. 2010, 17, 2442–2455. [Google Scholar] [CrossRef]
  65. Chatterjee, K.; AlSharif, D.; Mazza, C.; Syar, P.; Al Sharif, M.; Fata, J.E. Resveratrol and pterostilbene exhibit anticancer properties involving the downregulation of HPV oncoprotein E6 in cervical cancer cells. Nutrients 2018, 10, 243. [Google Scholar] [CrossRef] [PubMed]
  66. Paul, S.; Rimando, A.M.; Lee, H.J.; Ji, Y.; Reddy, B.S.; Suh, N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev. Res. 2009, 2, 650–657. [Google Scholar]
  67. Nutakul, W.; Sobers, H.S.; Qiu, P.; Dong, P.; Decker, E.A.; McClements, D.J.; Xiao, H. Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: A side-by-side comparison. J. Agric. Food Chem. 2011, 59, 10964–10970. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Jawad, R.A.M.; Sahib, H.B. Estimation the Safety of Parenteral Resveratrol in Mice. Iraqi J. Pharm. Sci. 2022, 31, 167–175. [Google Scholar]
  69. Sun, L.; Chen, B.; Jiang, R.; Li, J.; Wang, B. Resveratrol inhibits lung cancer growth by suppressing M2-like polarization of tumor associated macrophages. Cell. Immunol. 2017, 311, 86–93. [Google Scholar] [CrossRef]
  70. Nguyen, A.V.; Martinez, M.; Stamos, M.J.; Moyer, M.P.; Planutis, K.; Hope, C.; Holcombe, R.F. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag. Res. 2009, 1, 25. [Google Scholar]
  71. Patel, K.R.; Brown, V.A.; Jones, D.J.; Britton, R.G.; Hemingway, D.; Miller, A.S.; West, K.P.; Booth, T.D.; Perloff, M.; Crowell, J.A. Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer PatientsResveratrol in Colorectal Cancer Patients. Cancer Res. 2010, 70, 7392–7399. [Google Scholar] [CrossRef]
  72. Howells, L.M.; Berry, D.P.; Elliott, P.J.; Jacobson, E.W.; Hoffmann, E.; Hegarty, B.; Brown, K.; Steward, W.; Gescher, A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—Safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419–1425. [Google Scholar] [CrossRef]
  73. Varoni, E.M.; Lo Faro, A.F.; Sharifi-Rad, J.; Iriti, M. Anticancer molecular mechanisms of resveratrol. Front. Nutr. 2016, 3, 8. [Google Scholar] [CrossRef]
  74. Chun, Y.J.; Kim, M.Y.; Guengerich, F. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 1999, 262, 20–24. [Google Scholar] [CrossRef]
  75. Diaz-Gerevini, G.T.; Repossi, G.; Dain, A.; Tarres, M.C.; Das, U.N.; Eynard, A.R. Beneficial action of resveratrol: How and why? Nutrition 2016, 32, 174–178. [Google Scholar] [CrossRef]
  76. Gupta, S.C.; Kannappan, R.; Reuter, S.; Kim, J.H.; Aggarwal, B.B. Chemosensitization of tumors by resveratrol. Ann. New York Acad. Sci. 2011, 1215, 150–160. [Google Scholar] [CrossRef]
  77. Fulda, S.; Debatin, K.-M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004, 23, 6702–6711. [Google Scholar] [CrossRef]
  78. Lin, C.-J.; Lee, C.-C.; Shih, Y.-L.; Lin, T.-Y.; Wang, S.-H.; Lin, Y.-F.; Shih, C.-M. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic. Biol. Med. 2012, 52, 377–391. [Google Scholar] [CrossRef]
  79. Gatouillat, G.; Balasse, E.; Joseph-Pietras, D.; Morjani, H.; Madoulet, C. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J. Cell. Biochem. 2010, 110, 893–902. [Google Scholar] [CrossRef]
  80. Malhotra, A.; Nair, P.; Dhawan, D.K. Curcumin and resveratrol synergistically stimulate p21 and regulate cox-2 by maintaining adequate zinc levels during lung carcinogenesis. Eur. J. Cancer Prev. 2011, 20, 411–416. [Google Scholar] [CrossRef]
  81. Kisková, T.; Ekmekcioglu, C.; Garajová, M.; Orendas, P.; Bojková, B.; Bobrov, N.; Jäger, W.; Kassayová, M.; Thalhammer, T. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Eur. J. Cancer Prev. 2012, 21, 163–170. [Google Scholar] [CrossRef]
  82. Castillo-Pichardo, L.; Dharmawardhane, S.F. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr. Cancer 2012, 64, 1058–1069. [Google Scholar] [CrossRef]
  83. Lampe, J.W.; Nishino, Y.; Ray, R.M.; Wu, C.; Li, W.; Lin, M.-G.; Gao, D.L.; Hu, Y.; Shannon, J.; Stalsberg, H.; et al. Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China. Cancer Epidemiol. Biomark. Prev. 2007, 16, 2579–2586. [Google Scholar] [CrossRef]
  84. Vitale, D.C.; Piazza, C.; Melilli, B.; Drago, F.; Salomone, S. Isoflavones: Estrogenic activity, biological effect and bioavailability. Eur. J. Drug Metab. Pharmacokinet. 2013, 38, 15–25. [Google Scholar] [CrossRef]
  85. Shin, S.B.; Woo, S.U.; Chin, Y.W.; Jang, Y.J.; Yim, H. Sensitivity of TP53-mutated cancer cells to the phytoestrogen genistein is associated with direct inhibition of Plk1 activity. J. Cell. Physiol. 2017, 232, 2818–2828. [Google Scholar] [CrossRef]
  86. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.-i.; Itoh, N.; Shibuya, M.; Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592–5595. [Google Scholar] [CrossRef]
  87. Paniagua-Pérez, R.; Reyes-Cadena, S.; Martínez-Canseco, C.; Reyes-Legorreta, C.; Martínez-Castro, J.; Madrigal-Santillán, E.; Morales-González, J.; Cristóbal-Luna, J.; Álvarez-González, I.; Madrigal-Bujaidar, E. Cellular protection induced by genistein in mouse and its antioxidant capacity. Pharmacogn. Mag. 2019, 15, 520. [Google Scholar]
  88. Hsiao, Y.C.; Peng, S.F.; Lai, K.C.; Liao, C.L.; Huang, Y.P.; Lin, C.C.; Lin, M.L.; Liu, K.C.; Tsai, C.C.; Ma, Y.-S.; et al. Genistein induces apoptosis in vitro and has antitumor activity against human leukemia HL-60 cancer cell xenograft growth in vivo. Environ. Toxicol. 2019, 34, 443–456. [Google Scholar] [CrossRef]
  89. Si, H.; Liu, D. Phytochemical genistein in the regulation of vascular function: New insights. Curr. Med. Chem. 2007, 14, 2581–2589. [Google Scholar] [CrossRef]
  90. Marini, H.; Minutoli, L.; Polito, F.; Bitto, A.; Altavilla, D.; Atteritano, M.; Gaudio, A.; Mazzaferro, S.; Frisina, A.; Frisina, N.; et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial. Ann. Intern. Med. 2007, 146, 839–847. [Google Scholar] [CrossRef]
  91. Sakla, M.S.; Shenouda, N.S.; Ansell, P.J.; MacDonald, R.S.; Lubahn, D.B. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine 2007, 32, 69–78. [Google Scholar] [CrossRef] [PubMed]
  92. Abler, A.; Smith, J.; Randazzo, P.; Rothenberg, P.; Jarett, L. Genistein differentially inhibits postreceptor effects of insulin in rat adipocytes without inhibiting the insulin receptor kinase. J. Biol. Chem. 1992, 267, 3946–3951. [Google Scholar] [CrossRef]
  93. Okura, A.; Arakawa, H.; Oka, H.; Yoshinari, T.; Monden, Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun. 1988, 157, 183–189. [Google Scholar] [CrossRef]
  94. Evans, B.A.J.; Griffiths, K.; Morton, M. Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol. 1995, 147, 295–302. [Google Scholar] [CrossRef] [PubMed]
  95. Huang, J.; Nasr, M.; Kim, Y.; Matthews, H. Genistein inhibits protein histidine kinase. J. Biol. Chem. 1992, 267, 15511–15515. [Google Scholar] [CrossRef]
  96. Tuli, H.S.; Tuorkey, M.J.; Thakral, F.; Sak, K.; Kumar, M.; Sharma, A.K.; Sharma, U.; Jain, A.; Aggarwal, V.; Bishayee, A. Molecular mechanisms of action of genistein in cancer: Recent advances. Front. Pharmacol. 2019, 10, 1336. [Google Scholar] [CrossRef]
  97. Hwang, J.T.; Lee, Y.K.; Shin, J.I.; Park, O.J. Anti-inflammatory and Anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. Ann. N. Y. Acad. Sci. 2009, 1171, 415–420. [Google Scholar] [CrossRef]
  98. Sanaei, M.; Kavoosi, F.; Pourahmadi, M.; Moosavi, S.N. Effect of Genistein and 17-β Estradiol on the Viability and Apoptosis of Human Hepatocellular Carcinoma HepG2 cell line. Adv. Biomed. Res. 2017, 6, 163. [Google Scholar]
  99. Suzuki, R.; Kang, Y.a.; Li, X.; Roife, D.; Zhang, R.; Fleming, J.B. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res. 2014, 34, 4685–4692. [Google Scholar]
  100. Ahn, J.C.; Biswas, R.; Chung, P.S. Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic thyroid cancer cells. Lasers Surg. Med. 2012, 44, 840–849. [Google Scholar] [CrossRef]
  101. Paul, B.; Li, Y.; Tollefsbol, T.O. The effects of combinatorial genistein and sulforaphane in breast tumor inhibition: Role in epigenetic regulation. Int. J. Mol. Sci. 2018, 19, 1754. [Google Scholar] [CrossRef]
  102. Eng, Q.Y.; Thanikachalam, P.V.; Ramamurthy, S. Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases. J. Ethnopharmacol. 2018, 210, 296–310. [Google Scholar] [CrossRef]
  103. Zhong, Y.; Ma, C.-M.; Shahidi, F. Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives. J. Funct. Foods 2012, 4, 87–93. [Google Scholar] [CrossRef]
  104. Galati, G.; Lin, A.; Sultan, A.M.; O’Brien, P.J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free. Radic. Biol. Med. 2006, 40, 570–580. [Google Scholar] [CrossRef]
  105. Almatroodi, S.A.; Almatroudi, A.; Khan, A.A.; Alhumaydhi, F.A.; Alsahli, M.A.; Rahmani, A.H. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules 2020, 25, 3146. [Google Scholar] [CrossRef]
  106. Huang, C.-Y.; Han, Z.; Li, X.; Xie, H.-H.; Zhu, S.-S. Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol. Lett. 2017, 14, 3623–3627. [Google Scholar] [CrossRef]
  107. Liu, L.; Hou, L.; Gu, S.; Zuo, X.; Meng, D.; Luo, M.; Zhang, X.; Huang, S.; Zhao, X. Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo. Oncol. Rep. 2015, 33, 297–303. [Google Scholar] [CrossRef]
  108. Landis-Piwowar, K.; Chen, D.; Foldes, R.; Chan, T.-H.; Dou, Q.P. Novel epigallocatechin gallate analogs as potential anticancer agents: A patent review (2009–present). Expert Opin. Ther. Pat. 2013, 23, 189–202. [Google Scholar] [CrossRef]
  109. Huang, J.; Chen, S.; Shi, Y.; Li, C.-H.; Wang, X.J.; Li, F.J.; Wang, C.H.; Meng, Q.H.; Zhong, J.N.; Liu, M. Epigallocatechin gallate from green tea exhibits potent an-ticancer effects in A-549 non-small lung cancer cells by inducing apoptosis, cell cycle arrest and inhibition of cell migration. J. BUON 2017, 22, 1422–1427. [Google Scholar]
  110. Moradzadeh, M.; Hosseini, A.; Erfanian, S.; Rezaei, H. Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase. Pharmacol. Rep. 2017, 69, 924–928. [Google Scholar] [CrossRef]
  111. Isbrucker, R.A.; Edwards, J.A.; Wolz, E.; Davidovich, A.; Bausch, J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: Dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 2006, 44, 636–650. [Google Scholar] [CrossRef] [PubMed]
  112. Shanafelt, T.D.; Lee, Y.K.; Geyer, S.M.; Grote, D.; Stenson, M.; Zincke, S.; Ansell, S.M.; Witzig, T.E.; Kay, N.E. The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism. Blood 2006, 108, 234. [Google Scholar] [CrossRef]
  113. Flores-Pérez, A.; Marchat, L.A.; Sánchez, L.L.; Romero-Zamora, D.; Arechaga-Ocampo, E.; Ramírez-Torres, N.; Chávez, J.D.; Carlos-Reyes, Á.; Astudillo-de la Vega, H.; Ruiz-García, E. Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non-small cells lung cancer to chemotherapy. PROTEOMICS–Clin. Appl. 2016, 10, 172–182. [Google Scholar] [CrossRef] [PubMed]
  114. Luo, K.-W.; Chen, W.; Lung, W.-Y.; Wei, X.-Y.; Cheng, B.-H.; Cai, Z.-M.; Huang, W.-R. EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-κB and MMP-9. J. Nutr. Biochem. 2017, 41, 56–64. [Google Scholar] [CrossRef] [PubMed]
  115. Zan, L.; Chen, Q.; Zhang, L.; Li, X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25. Bioengineered 2019, 10, 374–382. [Google Scholar] [CrossRef]
  116. Eom, D.-W.; Lee, J.H.; Kim, Y.-J.; Hwang, G.S.; Kim, S.-N.; Kwak, J.H.; Cheon, G.J.; Kim, K.H.; Jang, H.-J.; Ham, J.; et al. Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep. 2015, 48, 461. [Google Scholar] [CrossRef]
  117. Moreira, L.; Araújo, I.; Costa, T.; Correia-Branco, A.; Faria, A.; Martel, F.; Keating, E. Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp. Cell Res. 2013, 319, 1784–1795. [Google Scholar] [CrossRef]
  118. Tan, M.; Norwood, A.; May, M.Y.; Tucci, M.; Benghuzzi, H. Effects of (-) epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomed. Sci. Instrum. 2006, 42, 363–371. [Google Scholar]
  119. Chen, H.; Landen, C.N.; Li, Y.; Alvarez, R.D.; Tollefsbol, T. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp. Cell Res. 2013, 319, 697–706. [Google Scholar] [CrossRef]
  120. Amin, A.; Wang, D.; Nannapaneni, S.; Lamichhane, R.; Chen, Z.G.; Shin, D.M. Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth in vivo in head and neck cancer models. Oncol. Rep. 2021, 45, 87. [Google Scholar] [CrossRef]
  121. Wei, R.; Wirkus, J.; Yang, Z.; Machuca, J.; Esparza, Y.; Mackenzie, G.G. EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines. Arch. Biochem. Biophys. 2020, 692, 108546. [Google Scholar] [CrossRef]
  122. La, X.; Zhang, L.; Li, Z.; Li, H.; Yang, Y. (−)-Epigallocatechin Gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-κB/miR-155-5p/MDR1 pathway. J. Agric. Food Chem. 2019, 67, 2510–2518. [Google Scholar] [CrossRef]
  123. Wang, X.; Jiang, P.; Wang, P.; Yang, C.S.; Wang, X.; Feng, Q. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PloS ONE 2015, 10, e0125402. [Google Scholar]
  124. Hu, F.; Wei, F.; Wang, Y.; Wu, B.; Fang, Y.; Xiong, B. EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. J. Pharmacol. Sci. 2015, 128, 27–34. [Google Scholar] [CrossRef]
  125. Kilic, U.; Sahin, K.; Tuzcu, M.; Basak, N.; Orhan, C.; Elibol-Can, B.; Kilic, E.; Sahin, F.; Kucuk, O. Enhancement of cisplatin sensitivity in human cervical cancer: Epigallocatechin-3-gallate. Front. Nutr. 2015, 1, 28. [Google Scholar] [CrossRef] [Green Version]
  126. Scandlyn, M.; Stuart, E.; Somers-Edgar, T.; Menzies, A.; Rosengren, R.J. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br. J. Cancer 2008, 99, 1056–1063. [Google Scholar] [CrossRef]
  127. Luo, T.; Wang, J.; Yin, Y.; Hua, H.; Jing, J.; Sun, X.; Li, M.; Zhang, Y.; Jiang, Y. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 2010, 12, R8. [Google Scholar] [CrossRef]
  128. Liu, J.; Zhong, T.; Yi, P.; Fan, C.; Zhang, Z.; Liang, G.; Xu, Y.; Fan, Y. A new epigallocatechin gallate derivative isolated from Anhua dark tea sensitizes the chemosensitivity of gefitinib via the suppression of PI3K/mTOR and epithelial-mesenchymal transition. Fitoterapia 2020, 143, 104590. [Google Scholar] [CrossRef]
  129. Haque, A.; Rahman, M.A.; Chen, Z.G.; Saba, N.F.; Khuri, F.R.; Shin, D.M.; Ruhul Amin, A.J.A. Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. Apoptosi 2015, 20, 986–995. [Google Scholar] [CrossRef]
  130. Borlinghaus, J.; Albrecht, F.; Gruhlke, M.C.; Nwachukwu, I.D.; Slusarenko, A.J. Allicin: Chemistry and biological properties. Molecules 2014, 19, 12591–12618. [Google Scholar] [CrossRef]
  131. Ha, M.W.; Yuan, Y. Allicin induced cell cycle arrest in human gastric cancer cell lines. Zhonghua Zhong Liu Za Zhi [Chin. J. Oncol.] 2004, 26, 585–589. [Google Scholar]
  132. Hirsch, K.; Danilenko, M.; Giat, J.; Miron, T.; Rabinkov, A.; Wilchek, M.; Mirelman, D.; Levy, J.; Sharoni, Y. Effect of purified allicin, the major ingredient offreshly crushed garlic, on cancer cell proliferation. Nutr. Cancer 2000, 38, 245–254. [Google Scholar] [CrossRef]
  133. Loría Gutiérrez, A.; Blanco Barrantes, J.; Porras Navarro, M.; Ortega Monge, M.C.; Cerdas Vargas, M.J.; Madrigal Redondo, G.L. Aspectos generales del Allium sativum-una revisión. Ars Pharm. (Internet) 2021, 62, 471–481. [Google Scholar]
  134. Jian, W.; Hui-juan, H.; Cheng-wei, H.; Ping, W.; Jian-jun, L. Effect of Allicin in antagonizing mice’s bladder cancer in vitro and in vivo. Chin. J. Integr. Med. 2004, 10, 208–212. [Google Scholar] [CrossRef]
  135. Cha, J.H.; Choi, Y.J.; Cha, S.H.; Choi, C.H.; Cho, W.H. Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway. Oncol. Rep. 2012, 28, 41–48. [Google Scholar] [CrossRef]
  136. Ankri, S.; Mirelman, D. Antimicrobial properties of allicin from garlic. Microbes Infect. 1999, 1, 125–129. [Google Scholar] [CrossRef]
  137. Marón, F.J.M.; Camargo, A.B.; Manucha, W. Allicin pharmacology: Common molecular mechanisms against neuroinflammation and cardiovascular diseases. Life Sci. 2020, 249, 117513. [Google Scholar] [CrossRef]
  138. Catanzaro, E.; Canistro, D.; Pellicioni, V.; Vivarelli, F.; Fimognari, C. Anticancer potential of allicin: A review. Pharmacol. Res. 2022, 177, 106118. [Google Scholar] [CrossRef]
  139. Sarvizadeh, M.; Hasanpour, O.; Ghale-Noie, Z.N.; Mollazadeh, S.; Rezaei, M.; Pourghadamyari, H.; Khooy, M.M.; Aschner, M.; Khan, H.; Rezaei, N.; et al. Allicin and digestive system cancers: From chemical structure to its therapeutic opportunities. Front. Oncol. 2021, 11, 650256. [Google Scholar] [CrossRef]
  140. Li, C.; Jing, H.; Ma, G.; Liang, P. Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells. Mol. Med. Rep. 2018, 17, 5976–5981. [Google Scholar] [CrossRef]
  141. Mahdy, E.M.; Abdu, S.M.; El Baseer, M.A. Effect of thymoquinone and allicin on some antioxidant parameters in cancer prostate (PC3) and colon cancer (Caco2) cell lines. Sci. J. Al-Azhar Med Fac. Girls 2020, 4, 85. [Google Scholar]
  142. Talib, W.H. Consumption of garlic and lemon aqueous extracts combination reduces tumor burden by angiogenesis inhibition, apoptosis induction, and immune system modulation. Nutrition 2017, 43, 89–97. [Google Scholar] [CrossRef]
  143. Sarkhani, E.; Najafzadeh, N.; Tata, N.; Dastan, M.; Mazani, M.; Arzanlou, M. Molecular mechanisms of methylsulfonylmethane and allicin in the inhibition of CD44±breast cancer cells growth. Funct. Foods 2017, 39, 50–57. [Google Scholar] [CrossRef]
  144. Pandey, N.; Tyagi, G.; Kaur, P.; Pradhan, S.; Rajam, M.V.; Srivastava, T. Allicin overcomes hypoxia mediated cisplatin resistance in lung cancer cells through ROS mediated cell death pathway and by suppressing hypoxia inducible factors. Cell. Physiol. Biochem. 2020, 54, 748–766. [Google Scholar] [PubMed]
  145. Țigu, A.B.; Toma, V.-A.; Moț, A.C.; Jurj, A.; Moldovan, C.S.; Fischer-Fodor, E.; Berindan-Neagoe, I.; Pârvu, M. The synergistic antitumor effect of 5-fluorouracil combined with allicin against lung and colorectal carcinoma cells. Molecules 2020, 25, 1947. [Google Scholar] [CrossRef] [PubMed]
  146. Khakbaz, P.; Panahizadeh, R.; Vatankhah, M.A.; Najafzadeh, N. Allicin Reduces 5-fluorouracil-resistance in Gastric Cancer Cells through Modulating MDR1, DKK1, and WNT5A Expression. Drug Res. 2021, 71, 448–454. [Google Scholar] [CrossRef]
  147. Fayin, W.U.; Haili, X.U. Effect and mechanism of allicin combined with 5-fluorouracil on proliferation and apoptosis of the MEC-1 cell line in mucoepidermoid carcinoma. J. Prev. Treat. Stomatol. Dis. 2020, 28, 355. [Google Scholar]
  148. Zhang, X.; Shao, S.; Li, F.; Zhang, W. Combination of Allicin and Adriamycin Inhibits Proliferation and Induces Apoptosis in Human Gastric SGC-7901cell. Nat. Prod. Res. Dev. 2014, 26, 309. [Google Scholar]
  149. Rahimi, M.P.; Hashemi, S.H.; Ghazinejhadian, S.F. Effect of Allicin on Tamoxifen-sensitive MCF-7 Breast Cancer Cells. J. Med. Plants 2015, 14, 101–110. [Google Scholar]
  150. Wu, X.; Li, X.; Song, Y.; Li, H.; Bai, X.; Liu, W.; Han, Y.; Xu, L.; Li, J.; Zhang, D.; et al. Allicin protects auditory hair cells and spiral ganglion neurons from cisplatin-induced apoptosis. Neuropharmacology 2017, 116, 429–440. [Google Scholar] [CrossRef]
  151. Wu, X.; Cai, J.; Li, X.; Li, H.; Li, J.; Bai, X.; Liu, W.; Han, Y.; Xu, L.; Zhang, D.; et al. Allicin protects against cisplatin-induced vestibular dysfunction by inhibiting the apoptotic pathway. Eur. J. Pharmacol. 2017, 805, 108–117. [Google Scholar] [CrossRef]
  152. Abdel-Daim, M.M.; Abushouk, A.I.; Donia, T.; Alarifi, S.; Alkahtani, S.; Aleya, L.; Bungau, S.G. The nephroprotective effects of allicin and ascorbic acid against cisplatin-induced toxicity in rats. Environ. Sci. Pollut. Res. 2019, 26, 13502–13509. [Google Scholar] [CrossRef]
  153. Abdel-Daim, M.M.; Khalifa, H.A.; Ahmed, A.A. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Cancer Chemother. Pharmacol. 2017, 80, 745–753. [Google Scholar] [CrossRef]
  154. Zou, X.; Liang, J.; Sun, J.; Hu, X.; Lei, L.; Wu, D.; Liu, L. Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway. J. Pharmacol. Sci. 2016, 131, 233–240. [Google Scholar] [CrossRef]
  155. Talebi, M.; Talebi, M.; Farkhondeh, T.; Samarghandian, S. Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway. Phytother. Res. 2021, 35, 1739–1753. [Google Scholar] [CrossRef]
  156. Badary, O.A.; Hamza, M.S.; Tikamdas, R. Thymoquinone: A promising natural compound with potential benefits for COVID-19 prevention and cure. Drug Des. Dev. Ther. 2021, 15, 1819. [Google Scholar] [CrossRef]
  157. Farkhondeh, T.; Samarghandian, S.; Shahri, A.M.P.; Samini, F. The neuroprotective effects of thymoquinone: A review. Dose-Response 2018, 16, 1559325818761455. [Google Scholar] [CrossRef]
  158. Alobaedi, O.H.; Talib, W.H.; Basheti, I.A. Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. Asian Pac. J. Trop. Med. 2017, 10, 400–408. [Google Scholar] [CrossRef]
  159. Kou, B.; Liu, W.; Zhao, W.; Duan, P.; Yang, Y.; Yi, Q.; Guo, F.; Li, J.; Zhou, J.; Kou, Q. Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. Oncol. Rep. 2017, 38, 3592–3598. [Google Scholar] [CrossRef]
  160. Feng, L.-M.; Wang, X.-F.; Huang, Q.-X. Thymoquinone induces cytotoxicity and reprogramming of EMT in gastric cancer cells by targeting PI3K/Akt/mTOR pathway. J. Biosci. 2017, 42, 547–554. [Google Scholar] [CrossRef]
  161. Zhang, M.; Du, H.; Huang, Z.; Zhang, P.; Yue, Y.; Wang, W.; Liu, W.; Zeng, J.; Ma, J.; Chen, G. Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway. Chem. -Biol. Interact. 2018, 292, 65–75. [Google Scholar] [CrossRef]
  162. Ismail, N.; Abdel–Mottaleb, Y.; Ahmed, A.A.E.; El-Maraghy, N.N. Novel combination of thymoquinone and resveratrol enhances anticancer effect on hepatocellular carcinoma cell line. Future J. Pharm. Sci. 2018, 4, 41–46. [Google Scholar] [CrossRef]
  163. Mashayekhi-Sardoo, H.; Rezaee, R.; Karimi, G. An overview of in vivo toxicological profile of thymoquinone. Toxin Rev. 2018, 39, 115–122. [Google Scholar] [CrossRef]
  164. Attoub, S.; Sperandio, O.; Raza, H.; Arafat, K.; Al-Salam, S.; Al Sultan, M.A.; Al Safi, M.; Takahashi, T.; Adem, A. Thymoquinone as an anticancer agent: Evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam. Clin. Pharmacol. 2013, 27, 557–569. [Google Scholar] [CrossRef] [PubMed]
  165. Khan, M.A.; Tania, M.; Fu, J. Epigenetic role of thymoquinone: Impact on cellular mechanism and cancer therapeutics. Drug Discov. Today 2019, 24, 2315–2322. [Google Scholar] [CrossRef]
  166. Mahmoud, Y.K.; Abdelrazek, H.M. Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed. Pharmacother. 2019, 115, 108783. [Google Scholar] [CrossRef]
  167. Farghaly, M.E.; Khowailed, A.A.; Aboulhoda, B.E.; Rashed, L.A.; Gaber, S.S.; Ashour, H. Thymoquinone potentiated the anticancer effect of cisplatin on hepatic tumorigenesis by modulating tissue oxidative stress and endoplasmic GRP78/CHOP signaling. Nutr. Cancer 2022, 74, 278–287. [Google Scholar] [CrossRef]
  168. Bashmail, H.A.; Alamoudi, A.A.; Noorwali, A.; Hegazy, G.A.; Ajabnoor, G.M.; Al-Abd, A.M. Thymoquinone enhances paclitaxel anti-breast cancer activity via inhibiting tumor-associated stem cells despite apparent mathematical antagonism. Molecules 2020, 25, 426. [Google Scholar] [CrossRef]
  169. Fatfat, M.; Fakhoury, I.; Habli, Z.; Mismar, R.; Gali-Muhtasib, H. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms. Life Sci. 2019, 232, 116628. [Google Scholar] [CrossRef]
  170. Mosalam, E.M.; Zidan, A.-A.A.; Mehanna, E.T.; Mesbah, N.M.; Abo-Elmatty, D.M. Thymoquinone and pentoxifylline enhance the chemotherapeutic effect of cisplatin by targeting Notch signaling pathway in mice. Life Sci. 2020, 244, 117299. [Google Scholar] [CrossRef]
  171. Odeh, L.H.; Talib, W.H.; Basheti, I.A. Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice. J. Cancer Res. Ther. 2018, 14, 324. [Google Scholar]
  172. Moubarak, M.M.; Chanouha, N.; Abou Ibrahim, N.; Khalife, H.; Gali-Muhtasib, H. Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer. World J. Clin. Oncol. 2021, 12, 342. [Google Scholar] [CrossRef]
  173. Al-Mutairi, A.; Rahman, A.; Rao, M.S. Low doses of thymoquinone and ferulic acid in combination effectively inhibit proliferation of cultured MDA-MB 231 breast adenocarcinoma cells. Nutr. Cancer 2021, 73, 282–289. [Google Scholar] [CrossRef] [PubMed]
  174. Alam, S.; Mohammad, T.; Padder, R.A.; Hassan, M.I.; Husain, M. Thymoquinone and quercetin induce enhanced apoptosis in non-small cell lung cancer in combination through the Bax/Bcl2 cascade. J. Cell. Biochem. 2022, 123, 259–274. [Google Scholar] [CrossRef] [PubMed]
  175. Aumeeruddy, M.Z.; Mahomoodally, M.F. Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone. Cancer 2019, 125, 1600–1611. [Google Scholar] [CrossRef] [PubMed]
  176. Zheng, J.; Zhou, Y.; Li, Y.; Xu, D.-P.; Li, S.; Li, H.-B. Spices for prevention and treatment of cancers. Nutrients 2016, 8, 495. [Google Scholar] [CrossRef]
  177. Tammina, S.K.; Mandal, B.K.; Ranjan, S.; Dasgupta, N. Cytotoxicity study of Piper nigrum seed mediated synthesized SnO2 nanoparticles towards colorectal (HCT116) and lung cancer (A549) cell lines. J. Photochem. Photobiol. B Biol. 2017, 166, 158–168. [Google Scholar] [CrossRef]
  178. Gunasekaran, V.; Elangovan, K.; Devaraj, S.N. Targeting hepatocellular carcinoma with piperine by radical-mediated mitochondrial pathway of apoptosis: An in vitro and in vivo study. Food Chem. Toxicol. 2017, 105, 106–118. [Google Scholar] [CrossRef]
  179. Li, N.; Wen, S.; Chen, G.; Wang, S. Antiproliferative potential of piperine and curcumin in drug-resistant human leukemia cancer cells are mediated via autophagy and apoptosis induction, S-phase cell cycle arrest and inhibition of cell invasion and migration. J. BUON 2020, 25, 401–406. [Google Scholar]
  180. Zhang, W.; Zheng, Q.; Song, M.; Xiao, J.; Cao, Y.; Huang, Q.; Ho, C.-T.; Lu, M. A review on the bioavailability, bio-efficacies and novel delivery systems for piperine. Food Funct. 2021, 12, 8867–8881. [Google Scholar] [CrossRef]
  181. Talib, W.H. Regressions of breast carcinoma syngraft following treatment with piperine in combination with thymoquinone. Sci. Pharm. 2017, 85, 27. [Google Scholar] [CrossRef]
  182. Lai, L.-H.; Fu, Q.-H.; Liu, Y.; Jiang, K.; Guo, Q.-M.; Chen, Q.-Y.; Yan, B.; Wang, Q.-Q.; Shen, J.-G. Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model. Acta Pharmacol. Sin. 2012, 33, 523–530. [Google Scholar] [CrossRef]
  183. Pradeep, C.; Kuttan, G. Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. Clin. Exp. Metastasis 2002, 19, 703–708. [Google Scholar] [CrossRef]
  184. Samykutty, A.; Shetty, A.V.; Dakshinamoorthy, G.; Bartik, M.M.; Johnson, G.L.; Webb, B.; Zheng, G.; Chen, A.; Kalyanasundaram, R.; Munirathinam, G. Piperine, a bioactive component of pepper spice exerts therapeutic effects on androgen dependent and androgen independent prostate cancer cells. PLoS ONE 2013, 8, e65889. [Google Scholar]
  185. Chowanski, S.; Adamski, Z.; Lubawy, J.; Marciniak, P.; Pacholska-Bogalska, J.; Slocinska, M.; Spochacz, M.; Szymczak, M.; Urbanski, A.; Walkowiak-Nowicka, K.; et al. Insect peptides–perspectives in human diseases treatment. Curr. Med. Chem. 2017, 24, 3116–3152. [Google Scholar] [CrossRef]
  186. Mittal, R.; Gupta, R. In vitro antioxidant activity of piperine. Methods Find. Exp. Clin. Pharmacol. 2000, 22, 271–274. [Google Scholar] [CrossRef]
  187. Srinivasan, K. Black pepper and its pungent principle-piperine: A review of diverse physiological effects. Crit. Rev. Food Sci. Nutr. 2007, 47, 735–748. [Google Scholar] [CrossRef]
  188. Fofaria, N.M.; Kim, S.-H.; Srivastava, S.K. Piperine causes G1 phase cell cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation. PLoS ONE 2014, 9, e94298. [Google Scholar] [CrossRef]
  189. Motiwala, M.; Rangari, V. Combined effect of paclitaxel and piperine on a MCF-7 breast cancer cell line in vitro: Evidence of a synergistic interaction. Synergy 2015, 2, 1–6. [Google Scholar] [CrossRef]
  190. Khamis, A.A.; Ali, E.M.; Abd El-Moneim, M.A.; Abd-Alhaseeb, M.M.; El-Magd, M.A.; Salim, E.I. Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. Biomed. Pharmacother. 2018, 105, 1335–1343. [Google Scholar] [CrossRef]
  191. Woo, C.C.; Hsu, A.; Kumar, A.P.; Sethi, G.; Tan, K.H.B. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: The role of p38 MAPK and ROS. PLoS ONE 2013, 8, e75356. [Google Scholar]
  192. Makhov, P.; Golovine, K.; Canter, D.; Kutikov, A.; Simhan, J.; Corlew, M.M.; Uzzo, R.G.; Kolenko, V.M. Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. Prostate 2012, 72, 661–667. [Google Scholar] [CrossRef]
  193. Semwal, R.B.; Semwal, D.K.; Combrinck, S.; Viljoen, A. Emodin-A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry 2021, 190, 112854. [Google Scholar] [CrossRef]
  194. Fang, L.; Zhao, F.; Iwanowycz, S.; Wang, J.; Yin, S.; Wang, Y.; Fan, D. Anticancer activity of emodin is associated with downregulation of CD155. Int. Immunopharmacol. 2019, 75, 105763. [Google Scholar] [CrossRef]
  195. Luo, N.; Fang, J.; Wei, L.; Sahebkar, A.; Little, P.J.; Xu, S.; Luo, C.; Li, G. Emodin in atherosclerosis prevention: Pharmacological actions and therapeutic potential. Eur. J. Pharmacol. 2021, 890, 173617. [Google Scholar] [CrossRef]
  196. Ya, C.; Liu-Jing, C.; Huang, T.; Jian-Qiong, Y.; Juan, L. The pharmacology, toxicology and therapeutic potential of anthraquinone derivative emodin. Chin. J. Nat. Med. 2020, 18, 425–435. [Google Scholar]
  197. Mitra, S.; Anjum, J.; Muni, M.; Das, R.; Rauf, A.; Islam, F.; Emran, T.B.; Semwal, P.; Hemeg, H.A.; Alhumaydhi, F.A. Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action. Biomed. Pharmacother. 2022, 149, 112877. [Google Scholar] [CrossRef]
  198. Li, Q.S.; Zhang, Y.; Zhang, S. Direct ab initio dynamics studies of the hydrogen abstraction reactions of hydrogen atom with n-propyl radical and isopropyl radical. J. Mol. Modeling 2005, 11, 41–47. [Google Scholar] [CrossRef]
  199. Chen, C.; Gao, J.; Wang, T.-S.; Guo, C.; Yan, Y.-J.; Mao, C.-Y.; Gu, L.-W.; Yang, Y.; Li, Z.-F.; Liu, A. NMR-based metabolomic techniques identify the toxicity of emodin in HepG2 cells. Sci. Rep. 2018, 8, 9379. [Google Scholar] [CrossRef]
  200. Lu, Y.; Yang, J.H.; Li, X.; Hwangbo, K.; Hwang, S.-L.; Taketomi, Y.; Murakami, M.; Chang, Y.-C.; Kim, C.-H.; Son, J.-K. Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochem. Pharmacol. 2011, 82, 1700–1708. [Google Scholar] [CrossRef]
  201. Liu, T.; Jin, H.; Sun, Q.-R.; Xu, J.-H.; Hu, H.-T. Neuroprotective effects of emodin in rat cortical neurons against β-amyloid-induced neurotoxicity. Brain Res. 2010, 1347, 149–160. [Google Scholar] [CrossRef]
  202. Xue, J.; Ding, W.; Liu, Y. Anti-diabetic effects of emodin involved in the activation of PPARγ on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010, 81, 173–177. [Google Scholar] [CrossRef]
  203. Hyun, S.K.; Lee, H.; Kang, S.S.; Chung, H.Y.; Choi, J.S. Inhibitory activities of Cassia tora and its anthraquinone constituents on angiotensin-converting enzyme. Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv. 2009, 23, 178–184. [Google Scholar] [CrossRef] [PubMed]
  204. Galiardi-Campoy, A.E.B.; Machado, F.C.; Carvalho, T.; Tedesco, A.C.; Rahal, P.; Calmon, M.F. Effects of photodynamic therapy mediated by emodin in cervical carcinoma cells. Photodiagnosis Photodyn. Ther. 2021, 35, 102394. [Google Scholar] [CrossRef] [PubMed]
  205. Lin, S.Z.; Chen, K.J.; Tong, H.F.; Jing, H.; Li, H.; Zheng, S.S. Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats. Clin. Exp. Pharmacol. Physiol. 2010, 37, 790–794. [Google Scholar] [CrossRef] [PubMed]
  206. Guo, H.; Liu, F.; Yang, S.; Xue, T. Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression. Oncol. Lett. 2020, 20, 167. [Google Scholar] [CrossRef] [PubMed]
  207. Kim, Y.-S.; Lee, Y.-M.; Oh, T.-I.; Shin, D.H.; Kim, G.-H.; Kan, S.-Y.; Kang, H.; Kim, J.H.; Kim, B.M.; Yim, W.J. Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. Int. J. Mol. Sci. 2018, 19, 3127. [Google Scholar] [CrossRef]
  208. Gupta, S.C.; Rai, V. Role of Emodin in Chemosensitization of Cancer. In Role of Nutraceuticals in Cancer Chemosensitization; Elsevier: Amsterdam, The Netherlands, 2018; pp. 241–257. [Google Scholar]
  209. Narender, T.; Sukanya, P.; Sharma, K.; Bathula, S.R. Apoptosis and DNA intercalating activities of novel emodin derivatives. RSC Adv. 2013, 3, 6123–6131. [Google Scholar] [CrossRef]
  210. Sun, Y.; Wang, X.; Zhou, Q.; Lu, Y.; Zhang, H.; Chen, Q.; Zhao, M.; Su, S. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol. Rep. 2015, 33, 338–346. [Google Scholar] [CrossRef]
  211. McDonald, S.J.; VanderVeen, B.N.; Velazquez, K.T.; Enos, R.T.; Fairman, C.M.; Cardaci, T.D.; Fan, D.; Murphy, E.A. Therapeutic Potential of Emodin for Gastrointestinal Cancers. Integr. Cancer Ther. 2022, 21, 15347354211067469. [Google Scholar] [CrossRef]
  212. Saunders, I.T.; Mir, H.; Kapur, N.; Singh, S. Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways. Cancer Cell Int. 2019, 19, 98. [Google Scholar] [CrossRef]
  213. Gu, J.; Cui, C.-f.; Yang, L.; Wang, L.; Jiang, X.-h. Emodin inhibits colon cancer cell invasion and migration by suppressing epithelial–mesenchymal transition via the Wnt/β-Catenin pathway. Oncol. Res. 2019, 27, 193. [Google Scholar] [CrossRef]
  214. Wang, Y.; Luo, Q.; He, X.; Wei, H.; Wang, T.; Shao, J.; Jiang, X. Emodin induces apoptosis of colon cancer cells via induction of autophagy in a ROS-dependent manner. Oncol. Res. 2018, 26, 889. [Google Scholar] [CrossRef]
  215. Lee, K.H.; Lee, M.S.; Cha, E.Y.; Sul, J.Y.; Lee, J.S.; Kim, J.S.; Park, J.B.; Kim, J.Y. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis. Mol. Med. Rep. 2017, 15, 2163–2173. [Google Scholar] [CrossRef]
  216. Wang, Z.; Chen, H.; Chen, J.; Hong, Z.; Liao, Y.; Zhang, Q.; Tong, H. Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway. Cancer Manag. Res. 2019, 11, 8463. [Google Scholar] [CrossRef]
  217. Teng, X.; Wang, S.Y.; Shi, Y.Q.; Fan, X.F.; Liu, S.; Xing, Y.; Guo, Y.Y.; Dong, M. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell. Anti-Cancer Drugs 2021, 32, 939–949. [Google Scholar] [CrossRef]
  218. Ding, N.; Zhang, H.; Su, S.; Ding, Y.; Yu, X.; Tang, Y.; Wang, Q.; Liu, P. Emodin enhances the chemosensitivity of endometrial cancer by inhibiting ROS-mediated Cisplatin-resistance. Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents) 2018, 18, 1054–1063. [Google Scholar] [CrossRef]
  219. Peng, S.; Wang, J.; Lu, C.; Xu, Z.; Chai, J.-J.; Ke, Q.; Deng, X.-Z. Emodin enhances cisplatin sensitivity in non-small cell lung cancer through Pgp downregulation. Oncol. Lett. 2021, 21, 230. [Google Scholar] [CrossRef]
  220. Ponnusamy, L.; Kothandan, G.; Manoharan, R. Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis. 2020, 1866, 165897. [Google Scholar]
  221. Sztiller-Sikorska, M.; Czyz, M. Parthenolide as cooperating agent for anti-cancer treatment of various malignancies. Pharmaceuticals 2020, 13, 194. [Google Scholar] [CrossRef]
  222. Alwaseem, H.; Frisch, B.J.; Fasan, R. Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis. Bioorganic Med. Chem. 2018, 26, 1365–1373. [Google Scholar] [CrossRef]
  223. Karam, L.; Abou Staiteieh, S.; Chaaban, R.; Hayar, B.; Ismail, B.; Neipel, F.; Darwiche, N.; Abou Merhi, R. Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. Mol. Carcinog. 2021, 60, 567–581. [Google Scholar] [CrossRef]
  224. Seca, A.M.; Silva, A.M.; Pinto, D.C. Parthenolide and parthenolide-like sesquiterpene lactones as multiple targets drugs: Current knowledge and new developments. Stud. Nat. Prod. Chem. 2017, 52, 337–372. [Google Scholar]
  225. Al-Fatlawi, A.A.; Al-Fatlawi, A.A.; Irshad, M.; Rahisuddin; Ahmad, A. Effect of parthenolide on growth and apoptosis regulatory genes of human cancer cell lines. Pharm. Biol. 2015, 53, 104–109. [Google Scholar] [CrossRef] [PubMed]
  226. Pooja, S.; Prashanth, S.; Suchetha, K.; Vidya, V.; Krishna, B. Evaluation of acute and sub acute toxicity of the leaf extract of Tanacetum parthenium (Asteraceae) and synthetic parthenolide. World J. Pharm. Pharm. Sci. 2016, 5, 703–713. [Google Scholar]
  227. Nakabayashi, H.; Shimizu, K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 2012, 12, 453. [Google Scholar] [CrossRef]
  228. Che, S.-T.; Bie, L.; Li, X.; Qi, H.; Yu, P.; Zuo, L. Parthenolide inhibits the proliferation and induces the apoptosis of human uveal melanoma cells. Int. J. Ophthalmol. 2019, 12, 1531. [Google Scholar] [CrossRef]
  229. Jafari, N.; Nazeri, S.; Enferadi, S.T. Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor α−1 expression. Phytomedicine 2018, 41, 67–73. [Google Scholar] [CrossRef]
  230. Talib, W.H.; Al Kury, L.T. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53-dependent apoptosis and inhibiting VEGF expression. Biomed. Pharmacother. 2018, 107, 1488–1495. [Google Scholar] [CrossRef]
  231. Kouhpaikar, H.; Sadeghian, M.H.; Rafatpanah, H.; Kazemi, M.; Iranshahi, M.; Delbari, Z.; Khodadadi, F.; Ayatollahi, H.; Rassouli, F.B. Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro. Iran. J. Basic Med. Sci. 2020, 23, 616. [Google Scholar]
  232. Kim, S.-L.; Kim, S.H.; Park, Y.R.; Liu, Y.-C.; Kim, E.-M.; Jeong, H.-J.; Kim, Y.N.; Seo, S.Y.; Kim, I.H.; Lee, S.O. Combined parthenolide and balsalazide have enhanced antitumor efficacy through blockade of NF-κB activation. Mol. Cancer Res. 2017, 15, 141–151. [Google Scholar] [CrossRef]
  233. Jin, X.; Zhou, J.; Zhang, Z.; Lv, H. The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis. Artif. Cells Nanomed. Biotechnol. 2018, 46, S931–S942. [Google Scholar] [CrossRef]
  234. Freund, R.R.; Gobrecht, P.; Fischer, D.; Arndt, H.-D. Advances in chemistry and bioactivity of parthenolide. Nat. Prod. Rep. 2020, 37, 541–565. [Google Scholar] [CrossRef]
  235. Cook, M.T. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer Targets Ther. 2018, 10, 89. [Google Scholar] [CrossRef]
  236. Nabavi, S.F.; Braidy, N.; Gortzi, O.; Sobarzo-Sanchez, E.; Daglia, M.; Skalicka-Woźniak, K.; Nabavi, S.M. Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Res. Bull. 2015, 119, 1–11. [Google Scholar] [CrossRef]
  237. da Silva, J.B.; de Freitas Mendes, R.; Tomasco, V.; Pinto, N.d.C.C.; de Oliveira, L.G.; Rodrigues, M.N.; de Oliveira Aragão, D.M.; de Aguiar, J.A.K.; Alves, M.S.; Castañon, M.C.N.M. New aspects on the hepatoprotective potential associated with the antioxidant, hypocholesterolemic and anti-inflammatory activities of Vernonia condensata Baker. J. Ethnopharmacol. 2017, 198, 399–406. [Google Scholar] [CrossRef]
  238. Seo, Y.; Ryu, K.; Park, J.; Jeon, D.-k.; Jo, S.; Lee, H.K.; Namkung, W. Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells. PLoS ONE 2017, 12, e0174935. [Google Scholar] [CrossRef]
  239. Moayeri, A.; Azimi, M.; Karimi, E.; Aidy, A.; Abbasi, N. Attenuation of morphine withdrawal syndrome by prosopis farcta extract and its bioactive component luteolin in comparison with clonidine in rats. Med. Sci. Monit. Basic Res. 2018, 24, 151. [Google Scholar] [CrossRef]
  240. Chian, S.; Thapa, R.; Chi, Z.; Wang, X.J.; Tang, X. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem. Biophys. Res. Commun. 2014, 447, 602–608. [Google Scholar] [CrossRef]
  241. Ganai, S.A.; Sheikh, F.A.; Baba, Z.A.; Mir, M.A.; Mantoo, M.A.; Yatoo, M.A. Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytother. Res. 2021, 35, 3509–3532. [Google Scholar] [CrossRef]
  242. Mishan, M.A.; Khazeei Tabari, M.A.; Mahrooz, A.; Bagheri, A. Role of microRNAs in the anticancer effects of the flavonoid luteolin: A systematic review. Eur. J. Cancer Prev. 2021, 30, 413–421. [Google Scholar] [CrossRef]
  243. You, Y.; Wang, R.; Shao, N.; Zhi, F.; Yang, Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. OncoTargets Ther. 2019, 12, 2383. [Google Scholar] [CrossRef]
  244. Xu, H.; Yang, T.; Liu, X.; Tian, Y.; Chen, X.; Yuan, R.; Su, S.; Lin, X.; Du, G. Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism. Life Sci. 2016, 144, 138–147. [Google Scholar] [CrossRef]
  245. Imran, M.; Rauf, A.; Abu-Izneid, T.; Nadeem, M.; Shariati, M.A.; Khan, I.A.; Imran, A.; Orhan, I.E.; Rizwan, M.; Atif, M. Luteolin, a flavonoid, as an anticancer agent: A review. Biomed. Pharmacother. 2019, 112, 108612. [Google Scholar] [CrossRef]
  246. Erdoğan, M.K.; Ağca, C.A.; Aşkın, H. Quercetin and luteolin improve the anticancer effects of 5-fluorouracil in human colorectal adenocarcinoma in vitro model: A mechanistic insight. Nutr. Cancer 2022, 74, 660–676. [Google Scholar] [CrossRef]
  247. Fan, J.-J.; Hsu, W.-H.; Lee, K.-H.; Chen, K.-C.; Lin, C.-W.; Lee, Y.-L.A.; Ko, T.-P.; Lee, L.-T.; Lee, M.-T.; Chang, M.-S. Dietary flavonoids luteolin and quercetin inhibit migration and invasion of squamous carcinoma through reduction of Src/Stat3/S100A7 signaling. Antioxidants 2019, 8, 557. [Google Scholar] [CrossRef]
  248. Lin, T.-H.; Hsu, W.-H.; Tsai, P.-H.; Huang, Y.-T.; Lin, C.-W.; Chen, K.-C.; Tsai, I.-H.; Kandaswami, C.C.; Huang, C.-J.; Chang, G.-D. Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial–mesenchymal transition signaling. Food Funct. 2017, 8, 1558–1568. [Google Scholar] [CrossRef]
  249. Magura, J.; Moodley, R.; Mackraj, I. The effect of hesperidin and luteolin isolated from Eriocephalus africanus on apoptosis, cell cycle and miRNA expression in MCF-7. J. Biomol. Struct. Dyn. 2022, 40, 1791–1800. [Google Scholar] [CrossRef]
  250. Chakrabarti, M.; Ray, S.K. Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells. Brain Res. 2015, 1629, 85–93. [Google Scholar] [CrossRef]
  251. Kelly, G.S. Quercetin. Monograph. Altern. Med. Rev. 2011, 16, 172–195. [Google Scholar]
  252. Boly, R.; Gras, T.; Lamkami, T.; Guissou, P.; Serteyn, D.; Kiss, R.; Dubois, J. Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int. J. Oncol. 2011, 38, 833–842. [Google Scholar]
  253. Hashemzaei, M.; Delarami Far, A.; Yari, A.; Heravi, R.E.; Tabrizian, K.; Taghdisi, S.M.; Sadegh, S.E.; Tsarouhas, K.; Kouretas, D.; Tzanakakis, G. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol. Rep. 2017, 38, 819–828. [Google Scholar] [CrossRef] [Green Version]
  254. Zhou, J.; Fang, L.; Liao, J.; Li, L.; Yao, W.; Xiong, Z.; Zhou, X. Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo. PLoS ONE 2017, 12, e0172838. [Google Scholar] [CrossRef] [PubMed]
  255. Palko-Labuz, A.; Sroda-Pomianek, K.; Uryga, A.; Kostrzewa-Suslow, E.; Michalak, K. Anticancer activity of baicalein and luteolin studied in colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells. Biomed. Pharmacother. 2017, 88, 232–241. [Google Scholar] [CrossRef] [PubMed]
  256. Kashyap, D.; Mittal, S.; Sak, K.; Singhal, P.; Tuli, H.S. Molecular mechanisms of action of quercetin in cancer: Recent advances. Tumor Biol. 2016, 37, 12927–12939. [Google Scholar] [CrossRef] [PubMed]
  257. Kedhari Sundaram, M.; Raina, R.; Afroze, N.; Bajbouj, K.; Hamad, M.; Haque, S.; Hussain, A. Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells. Biosci. Rep. 2019, 39, BSR20190720. [Google Scholar] [CrossRef]
  258. Kundur, S.; Prayag, A.; Selvakumar, P.; Nguyen, H.; McKee, L.; Cruz, C.; Srinivasan, A.; Shoyele, S.; Lakshmikuttyamma, A. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines. J. Cell. Physiol. 2019, 234, 11103–11118. [Google Scholar] [CrossRef]
  259. Mutlu Altundağ, E.; Yılmaz, A.M.; Koçtürk, S.; Taga, Y.; Yalçın, A.S. Synergistic induction of apoptosis by quercetin and curcumin in chronic myeloid leukemia (K562) cells. Nutr. Cancer 2018, 70, 97–108. [Google Scholar] [CrossRef]
  260. Singh, V.; Singh, R.; Kujur, P.K.; Singh, R.P. Combination of resveratrol and quercetin causes cell growth inhibition, DNA damage, cell cycle arrest, and apoptosis in oral cancer cells. ASSAY Drug Dev. Technol. 2020, 18, 226–238. [Google Scholar] [CrossRef]
  261. Imran, M.; Iqubal, M.K.; Imtiyaz, K.; Saleem, S.; Mittal, S.; Rizvi, M.M.A.; Ali, J.; Baboota, S. Topical nanostructured lipid carrier gel of quercetin and resveratrol: Formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer. Int. J. Pharm. 2020, 587, 119705. [Google Scholar] [CrossRef]
  262. Xu, W.; Xie, S.; Chen, X.; Pan, S.; Qian, H.; Zhu, X. Effects of quercetin on the efficacy of various chemotherapeutic drugs in cervical cancer cells. Drug Des. Dev. Ther. 2021, 15, 577. [Google Scholar] [CrossRef]
  263. Lotfi, M.; Kazemi, S.; Ebrahimpour, A.; Shirafkan, F.; Pirzadeh, M.; Hosseini, M.; Moghadamnia, A.A. Protective Effect of Quercetin Nanoemulsion on 5-Fluorouracil-Induced Oral Mucositis in Mice. J. Oncol. 2021, 2021, 5598230. [Google Scholar] [CrossRef]
  264. Wang, H.; Tao, L.; Qi, K.; Zhang, H.; Feng, D.; Wei, W.; Kong, H.; Chen, T.; Lin, Q. Quercetin reverses tamoxifen resistance in breast cancer cells. J. BUON 2015, 20, 707–713. [Google Scholar]
  265. Li, S.; Yuan, S.; Zhao, Q.; Wang, B.; Wang, X.; Li, K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed. Pharmacother. 2018, 100, 441–447. [Google Scholar] [CrossRef]
  266. Minaei, A.; Sabzichi, M.; Ramezani, F.; Hamishehkar, H.; Samadi, N. Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol. Biol. Rep. 2016, 43, 99–105. [Google Scholar] [CrossRef]
  267. Fang, J.; Zhang, S.; Xue, X.; Zhu, X.; Song, S.; Wang, B.; Jiang, L.; Qin, M.; Liang, H.; Gao, L. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. Int. J. Nanomed. 2018, 13, 5113. [Google Scholar] [CrossRef]
  268. Zhao, J.-l.; Zhao, J.; Jiao, H. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. Appl. Biochem. Biotechnol. 2014, 172, 784–791. [Google Scholar] [CrossRef]
  269. Yardim, A.; Kandemir, F.M.; Ozdemir, S.; Kucukler, S.; Comakli, S.; Gur, C.; Celik, H. Quercetin provides protection against the peripheral nerve damage caused by vincristine in rats by suppressing caspase 3, NF-κB, ATF-6 pathways and activating Nrf2, Akt pathways. NeuroToxicology 2020, 81, 137–146. [Google Scholar] [CrossRef]
  270. Zhang, X.; Huang, J.; Yu, C.; Xiang, L.; Li, L.; Shi, D.; Lin, F. Quercetin enhanced paclitaxel therapeutic effects towards PC-3 prostate cancer through ER stress induction and ROS production. OncoTargets Ther. 2020, 13, 513. [Google Scholar] [CrossRef]
  271. Liu, M.; Fu, M.; Yang, X.; Jia, G.; Shi, X.; Ji, J.; Liu, X.; Zhai, G.J. Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer. Colloids Surf. B Biointerfaces 2020, 196, 111284. [Google Scholar] [CrossRef]
  272. Huang, C.; Chen, T.; Zhu, D.; Huang, Q. Enhanced tumor targeting and radiotherapy by quercetin loaded biomimetic nanoparticles. Front. Chem. 2020, 8, 225. [Google Scholar] [CrossRef]
  273. Li, X.; Guo, S.; Xiong, X.-K.; Peng, B.-Y.; Huang, J.-M.; Chen, M.-F.; Wang, F.-Y.; Wang, J.-N. Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway. J. Cancer 2019, 10, 4509. [Google Scholar] [CrossRef]
  274. Liu, H.; Lee, J.I.; Ahn, T.-G. Effect of quercetin on the anti-tumor activity of cisplatin in EMT6 breast tumor-bearing mice. Obstet. Gynecol. Sci. 2019, 62, 242–248. [Google Scholar] [CrossRef]
  275. Sanchez-Gonzalez, P.D.; Lopez-Hernandez, F.J.; Perez-Barriocanal, F.; Morales, A.I.; Lopez-Novoa, J.M. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol. Dial. Transplant. 2011, 26, 3484–3495. [Google Scholar] [CrossRef]
  276. Mottaghipisheh, J.; Doustimotlagh, A.H.; Irajie, C.; Tanideh, N.; Barzegar, A.; Iraji, A. The promising therapeutic and preventive properties of anthocyanidins/anthocyanins on prostate cancer. Cells 2022, 11, 1070. [Google Scholar] [CrossRef]
  277. Khoo, H.E.; Azlan, A.; Tang, S.T.; Lim, S.M. Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Res. 2017, 61, 1361779. [Google Scholar] [CrossRef]
  278. Wallace, T.C. Anthocyanins in cardiovascular disease. Adv. Nutr. 2011, 2, 1–7. [Google Scholar] [CrossRef] [PubMed]
  279. Li, P.; Feng, D.; Yang, D.; Li, X.; Sun, J.; Wang, G.; Tian, L.; Jiang, X.; Bai, W. Protective effects of anthocyanins on neurodegenerative diseases. Trends Food Sci. Technol. 2021, 117, 205–217. [Google Scholar] [CrossRef]
  280. Jiang, X.; Li, X.; Zhu, C.; Sun, J.; Tian, L.; Chen, W.; Bai, W. The target cells of anthocyanins in metabolic syndrome. Crit. Rev. Food Sci. Nutr. 2019, 59, 921–946. [Google Scholar] [CrossRef]
  281. Lin, B.W.; Gong, C.C.; Song, H.F.; Cui, Y.Y. Effects of anthocyanins on the prevention and treatment of cancer. J. Cereb. Blood Flow Metab. 2017, 174, 1226–1243. [Google Scholar] [CrossRef]
  282. Bowen-Forbes, C.S.; Zhang, Y.; Nair, M.G. Anthocyanin content, antioxidant, anti-inflammatory and anticancer properties of blackberry and raspberry fruits. J. Food Compos. Anal. 2010, 23, 554–560. [Google Scholar] [CrossRef]
  283. Cladis, D.P.; Li, S.; Reddivari, L.; Cox, A.; Ferruzzi, M.G.; Weaver, C.M. A 90 day oral toxicity study of blueberry polyphenols in ovariectomized sprague-dawley rats. Food Chem. Toxicol. 2020, 139, 111254. [Google Scholar] [CrossRef] [PubMed]
  284. Ha, U.S.; Bae, W.J.; Kim, S.J.; Yoon, B.I.; Hong, S.H.; Lee, J.Y.; Hwang, T.-K.; Hwang, S.Y.; Wang, Z.; Kim, S.W. Anthocyanin induces apoptosis of DU-145 cells in vitro and inhibits xenograft growth of prostate cancer. Yonsei Med. J. 2015, 56, 16–23. [Google Scholar] [CrossRef] [Green Version]
  285. Hou, D.-X. Potential mechanisms of cancer chemoprevention by anthocyanins. Curr. Mol. Med. 2003, 3, 149–159. [Google Scholar] [CrossRef]
  286. Luo, L.-P.; Han, B.; Yu, X.-P.; Chen, X.-Y.; Zhou, J.; Chen, W.; Zhu, Y.-F.; Peng, X.-L.; Zou, Q.; Li, S.-Y. Anti-metastasis activity of black rice anthocyanins against breast cancer: Analyses using an ErbB2 positive breast cancer cell line and tumoral xenograft model. Asian Pac. J. Cancer Prev. 2014, 15, 6219–6225. [Google Scholar] [CrossRef]
  287. Yin, H.; Wang, L.; Wu, M.; Liu, Y.; Li, N.; Chen, T. Cyanidin-3-O-glucoside chloride acts synergistically with luteolin to inhibit the growth of colon and breast carcinoma cells. Die Pharm. 2019, 74, 54–61. [Google Scholar]
  288. Li, X.; Chen, L.; Gao, Y.; Zhang, Q.; Chang, A.K.; Yang, Z.; Bi, X. Black raspberry anthocyanins increased the antiproliferative effects of 5-Fluorouracil and Celecoxib in colorectal cancer cells and mouse model. J. Funct. Foods 2021, 87, 104801. [Google Scholar] [CrossRef]
  289. Paramanantham, A.; Kim, M.J.; Jung, E.J.; Kim, H.J.; Chang, S.-H.; Jung, J.-M.; Hong, S.C.; Shin, S.C.; Kim, G.S.; Lee, W.S. Anthocyanins isolated from vitis coignetiae pulliat enhances cisplatin sensitivity in MCF-7 human breast cancer cells through inhibition of Akt and NF-κB activation. Molecules 2020, 25, 3623. [Google Scholar] [CrossRef]
  290. Qian, P.; Yan, L.J.; Li, Y.Q.; Yang, H.T.; Duan, H.Y.; Wu, J.T.; Fan, X.W.; Wang, S.-L. Cyanidin ameliorates cisplatin-induced cardiotoxicity via inhibition of ROS-mediated apoptosis. Exp. Ther. Med. 2018, 15, 1959–1965. [Google Scholar] [CrossRef]
  291. Pepe, G.; Salviati, E.; Rapa, S.F.; Ostacolo, C.; Cascioferro, S.; Manfra, M.; Marzocco, S.; Campiglia, P. Citrus sinensis and vitis vinifera protect cardiomyocytes from doxorubicin-induced oxidative stress: Evaluation of onconutraceutical potential of vegetable smoothies. Antioxidants 2020, 9, 378. [Google Scholar] [CrossRef]
  292. Tancharoen, S.; Shakya, P.; Narkpinit, S.; Dararat, P.; Kikuchi, K.J. Anthocyanins extracted from Oryza sativa L. prevent fluorouracil-induced nuclear factor-κB activation in oral mucositis: In vitro and in vivo studies. Int. J. Mol. Sci. 2018, 19, 2981. [Google Scholar] [CrossRef]
  293. Tang, S.; Kan, J.; Sun, R.; Cai, H.; Hong, J.; Jin, C.; Zong, S. Anthocyanins from purple sweet potato alleviate doxorubicin-induced cardiotoxicity in vitro and in vivo. J. Food Biochem. 2021, 45, e13869. [Google Scholar] [CrossRef]
  294. Liu, W.; Xu, J.; Liu, Y.; Yu, X.; Tang, X.; Wang, Z.; Li, X. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Mol. Med. Rep. 2014, 10, 1921–1926. [Google Scholar] [CrossRef]
  295. Li, X.; Xu, J.; Tang, X.; Liu, Y.; Yu, X.; Wang, Z.; Liu, W. Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo. Mol. Med. Rep. 2016, 13, 4007–4013. [Google Scholar] [CrossRef] [Green Version]
  296. Qi, Z.L.; Wang, Z.; Li, W.; Hou, J.G.; Liu, Y.; Li, X.D.; Li, H.P.; Wang, Y.P. Nephroprotective effects of anthocyanin from the fruits of Panax ginseng (GFA) on cisplatin-induced acute kidney injury in mice. Phytotherapy Res. 2017, 31, 1400–1409. [Google Scholar] [CrossRef]
  297. de Gomes, M.G.; Del Fabbro, L.; Goes, A.T.R.; Souza, L.C.; Donato, F.; Boeira, S.P.; Prigol, M.; Jesse, C.R. Blackberry juice anthocyanidins limit cisplatin-induced renal pathophysiology in mice. Pathophysiology 2019, 26, 137–143. [Google Scholar] [CrossRef]
  298. Shi, L.; Liu, Y.-E.; Tan, D.-H.; Yan, T.-C.; Song, D.-Q.; Hou, M.-X.; Meng, X.-J. Blueberry anthocyanins ameliorate cyclophosphamide-induced liver damage in rats by reducing inflammation and apoptosis. J. Funct. Foods 2014, 11, 71–81. [Google Scholar] [CrossRef]
  299. Kim, Y.G.; Park, Y.H.; Yang, E.Y.; Park, W.S.; Park, K.S. Inhibition of tamoxifen’s therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines. Ann. Surg. Treat. Res. 2019, 97, 230–238. [Google Scholar] [CrossRef]
Molecules 27 05452 g001 550
Figure 1. Chemical structure of curcumin.
Figure 1. Chemical structure of curcumin.
Molecules 27 05452 g001
Molecules 27 05452 g002 550
Figure 2. Chemical structure of resveratrol. (a) Trans-resveratrol and (b) Cis-resveratrol.
Figure 2. Chemical structure of resveratrol. (a) Trans-resveratrol and (b) Cis-resveratrol.
Molecules 27 05452 g002
Molecules 27 05452 g003 550
Figure 3. Chemical structure of genistein.
Figure 3. Chemical structure of genistein.
Molecules 27 05452 g003
Molecules 27 05452 g004 550
Figure 4. Chemical structure of EGCG.
Figure 4. Chemical structure of EGCG.
Molecules 27 05452 g004
Molecules 27 05452 g005 550
Figure 5. Chemical structure of allicin.
Figure 5. Chemical structure of allicin.
Molecules 27 05452 g005
Molecules 27 05452 g006 550
Figure 6. Chemical structure of thymoquinone.
Figure 6. Chemical structure of thymoquinone.
Molecules 27 05452 g006
Molecules 27 05452 g007 550
Figure 7. Chemical structure of piperine.
Figure 7. Chemical structure of piperine.
Molecules 27 05452 g007
Molecules 27 05452 g008 550
Figure 8. Chemical structure of emodin.
Figure 8. Chemical structure of emodin.
Molecules 27 05452 g008
Molecules 27 05452 g009 550
Figure 9. Chemical structure of parthenolide.
Figure 9. Chemical structure of parthenolide.
Molecules 27 05452 g009
Molecules 27 05452 g010 550
Figure 10. Chemical structure of luteolin.
Figure 10. Chemical structure of luteolin.
Molecules 27 05452 g010
Molecules 27 05452 g011 550
Figure 11. Chemical structure of quercetin.
Figure 11. Chemical structure of quercetin.
Molecules 27 05452 g011
Molecules 27 05452 g012 550
Figure 12. Chemical structure of anthocyanins (cyanidin).
Figure 12. Chemical structure of anthocyanins (cyanidin).
Molecules 27 05452 g012
Molecules 27 05452 g013 550
Figure 13. A summary of the natural compounds with their combination therapy. QUR, quercetin; CUR, curcumin; TQ, Thymoquinone; LTN, Luteolin; ACN, anthocyanins; PTL, parthenolide; GNT, genistein; PIP, piperine; EMD, emodin; RES, resveratrol; ALN, allicin; CIS, cisplatin; DOX, doxorubicin; MT, melatonin; TMZ, temozolomide; Tmab, trastuzumab; TAM, tamoxifen; DTX, docetaxel; PTX, paclitaxel; CCB, celecoxib; CAPS, capsaicin; PF, photofrin; SFN, sulforaphane; GEF, gefitinib; ASC, ascorbic acid; ADM, Adriamycin; MSM, methylsulfonylmethane; RJ, royal jelly; PF, pentoxifylline; BV, bee venom; HES, hesperidin; BBR, berberine; SFB, sorafenib; AFT, afatinib; GEM, gemcitabine; ENDX, endoxifen; G-CK, ginsenoside compound k; G-Rh, ginsenoside Rh; EPR, epirubicin; ICG, indocyanine green; ATO, arsenic trioxide; BLZ, balsalazide; SB, silibinin; BCN, baicalein; VIN, vincristine; RT, radiotherapy.
Figure 13. A summary of the natural compounds with their combination therapy. QUR, quercetin; CUR, curcumin; TQ, Thymoquinone; LTN, Luteolin; ACN, anthocyanins; PTL, parthenolide; GNT, genistein; PIP, piperine; EMD, emodin; RES, resveratrol; ALN, allicin; CIS, cisplatin; DOX, doxorubicin; MT, melatonin; TMZ, temozolomide; Tmab, trastuzumab; TAM, tamoxifen; DTX, docetaxel; PTX, paclitaxel; CCB, celecoxib; CAPS, capsaicin; PF, photofrin; SFN, sulforaphane; GEF, gefitinib; ASC, ascorbic acid; ADM, Adriamycin; MSM, methylsulfonylmethane; RJ, royal jelly; PF, pentoxifylline; BV, bee venom; HES, hesperidin; BBR, berberine; SFB, sorafenib; AFT, afatinib; GEM, gemcitabine; ENDX, endoxifen; G-CK, ginsenoside compound k; G-Rh, ginsenoside Rh; EPR, epirubicin; ICG, indocyanine green; ATO, arsenic trioxide; BLZ, balsalazide; SB, silibinin; BCN, baicalein; VIN, vincristine; RT, radiotherapy.
Molecules 27 05452 g013
Table
Table 1. Combination of experimental design of natural compounds with other natural products and the outcomes of these studies.
Table 1. Combination of experimental design of natural compounds with other natural products and the outcomes of these studies.
Natural
Compounds		Chemical
Classification		Combination TherapyConcentrations UsedType of CancerExperimental ModelOutcomes of the CombinationIntersecting MechanismsReferences
CurcuminDiarylheptanoid, phenolic compoundCurcumin/ResveratrolCurcumin
15 mM
Resveratrol
15 μM		Breast cancer
Salivary cancer 		In vitroReducing cancer cell viability, increased ER stress and activation of the pro-death UPR protein CHOPApoptosis[49]
Curcumin/Soy isoflavonesCurcumin
20 mM
Isoflavones
10 mg/mL 		Prostate adenocarcinomaIn vitroReduced the concentration of PSA Anti-androgen effect[48]
Curcumin/Emodin Curcumin
30 μM
Emodin
80 μM		Breast cancer In vitroReduced tumor growth and invasion by inducing the expression of miR-34aInhibition of proliferation and invasion of breast cancer cells through upregulation of miR-34a[55]
Curcumin/
EGCG		Curcumin
3 mM
EGCG
25 μM		Breast cancerIn vitro
In vivo		Suppress ERα-breast cancer cell growthG2/M-phase cell cycle arrest[54]
Curcumin/Thmoquinone Curcumin 24.91 µM
TQ
41.16 µM		Breast cancerIn vitroShowed synergistic effect in reducing tumor cells growth via increasing caspase-3 and decrease PI3K and AKT Cell proliferation inhibition
Apoptosis induction		[56]
Curcumin/Gemcitabine Curcumin
10 μmol/L
Gemcitabine
50 nmol/L		Pancreatic cancerIn vitro
In vivo		Prevent the production, development, invasion, and metastasis of proteins (NF-B, EGFR, VEGF, COX-2, miRNA-22, Bcl-2, Bcl-xL, and others)
upregulating Bax and caspases		Inhibition of proliferation, angiogenesis, and invasion[58]
Curcumin/Vitamin DCurcumin
10−5 M
1.25D
10−7 M		Colon cancer In vitroImproved anticancer effect by interacting with vitamin D receptors Activating vitamin D receptor
(VDR) inducing the VDR target genes CYP3A4, CYP24, p21 and TRPV6. In the colon, some of these yet-to-be identified genes may play a role in cancer chemoprevention		[59]
Curcumin/Quercetin curcumin
3.1 μM and 6.2 μM
Quercetin
25 μM and 50 μM		Human malignant melanoma In vitroInhibition of proliferation, modulation of Wnt/β-catenin signaling and apoptotic pathway Inhibition of cell proliferation through down-regulation of Wnt/β-catenin signaling pathway proteins, DVL2, β-catenin, cyclin D1, Cox2, and Axin2 [60]
Curcumin/Boswellic acidcurcumin,
10 μmol/L
AKBA
30 μmol/L		Colorectal cancer In vitro
In vivo		Induced chemoprevention through modulating miRNAs and their downstream target genes involved in cell-cycle controlSuppression of tumor growth by
Induction the upregulation of tumor-suppressive miR-34a and downregulation of miR-27a in colorectal cancer cells		[47]
ResveratrolStilbeniod, phenolic compound, and a phytoalexin Resveratrol/CurcuminResveratrol
dose level
of 5.7 mg/mL three times a week
Curcumin
dose level
of 60 mg/kg
of body weight three times a week		Lung cancerIn vivo Synergistically stimulated p21 and modulated Cox-2 expression expression of p21
significant decrease in tumor incidence and multiplicity curcumin and resveratrol have been reported to modulate p21 expression by a p53-dependen pathway
adequate zinc levels along with phytochemicals resulted in efficient cell cycle arrest by p21 to control rapid cell proliferation		[80]
Resveratrol/Melatonin Resveratrol
pellets in a concentration of 100 mg/kg
Melatonin
Drinking water
pellets in a concentration of 100 mg/kg		Breast cancer In vivo NMU-induced mammary carcinogenesis was not affected by either agent alone, but when they were combined it resulted in a significant decrease in tumor incidence.reduced tumor incidence by approximately 17% and significantly decreased the quantity of invasive and in-situ carcinomas
returned food intake to the level of intact controls (significantly increased food intake) protective effects on NMU-induced rodent breast cancer		[81]
GenisteinPhytoestrogenic isoflavoneGenistein/Capsaicin genistein
50 μmol/L
Capsaicin
50 μmol/L		Breast cancerIn vitro Synergistic apoptotic and anti-inflammatory effects Reduced cell viability
chromatin condensation and nuclear fragmentation
stimulating AMPKα1		[97]
Genistein/SulforaphaneGenistein
15 µM
Sulforaphane
5 µM		Breast cancerIn vitroPromoted cell cycle arrest downregulated KLF4
downregulated HDAC activity
especially HDAC2 and HDAC3
downregulated
hTERT 		[101]
EGCGCatechin/polyphenol EGCG/curcumin EGCG
50 and 100 μM
curcumin
50 μM 		Prostate cancerIn vitroArrested S and G2/M cyclesArrested both S and G2/M phases of cell cycle
Synergic up-regulation of p21 and followed cell growth arrest		[116]
EGCG/QuercetinEGCG
100 μM
Quercetin
10 and 100 μM 		Breast cancer In vitroEGCG had improved the anti-metabolic effect of quercetin in ER-negative breast cancers also it had decreased the viability and proliferation of MCF7 cellsDecreased cellular proliferation
Inhibit glucose uptake by cells
Metabolic antagonists in breast cancer cells, independently of estrogen signaling		[117]
EGCG/ResveratrolEGCG
30 μM
resveratrol
15 μM 		Head and neck cancerIn vivoEnhanced apoptotic effect and reduced tumor growthIncreased apoptosis[120]
EGCG/SulforaphaneEGCG
20 mM
Sulforaphane
10 mM		 Ovarian cancer In vitroProvoked apoptosis in ovarian resistant cells through human telomerase reverse transcriptase(hTERT) and Bcl-2 down regulationarrest cells in both G2/M and S phase
increases apoptosis in paclitaxel-resistant SKOV3TR-ip2 cells
by down-regulating of hTERT and Bcl-2 and promote DNA damage response
reducing the expression of hTERT		[119]
AllicinThiosulfinate Allicin/
Thymoquinone		PC3 cells
Allicin
24 g/mL
Thymoquinone
500 g/mL
CaCo2 cell
Allicin
12 g/mL
Thymoquinone
500 g/mL		Prostate and colon cancer In vitroModulated antioxidant parameters Increase of catalase activity in both PC3 cells and Caco2 cell[141]
Allicin/MethylsulfonylmethaneThey used the IC50
MSM/allicin
For CD44−
55.71 ± 8.47 mg/mL
MSM/allicin
For CD44+
68.83 ± 9.78 mg/mL		Breast cancer In vitroIncreased expression of caspase-3 mRNA expressionEnhanced more caspase-3 mRNA expression than allicin alone in both CD44± cells.
Modulating the expression of the key apoptotic factors.		[143]
ThymoquinoneMonoterpenoid Thymoquinone/Royal jelly Thymoquinone
15 µmol/L
Royal jelly
5 µg/mL 		Breast cancerIn vitroEnhanced anticancer activity cell viability inhibition and PreG1 increase [172]
Thymoquinone/QuercetinThymoquinone
5 μM
Quercetin
22.49 and 25.9 μM		Non-small cell lung cancer In vitroInduced apoptosis by modulating Bax/Bcl2 cascadereduce the expression of antiapoptotic protein Bcl2 and induce proapoptotic Bax[174]
Thymoquinone/ferulic acid Thymoquinone
50 and 100 µM
ferulic acid
450 µM 		Breast adenocarcinomaIn vitroSynergic growth inhibition decreased cell proliferation [173]
Thymoquinone/MelatoninThymoquinone
10 mg/kg/day
Melatonin
1 mg/kg twice daily		Breast cancerIn vitro
In vivo		Synergic antitumor effect by reducing tumor size with a 60% cure induction of apoptosis, angiogenesis inhibition, and activation of T helper 1 anticancer immune response[171]
Thymoquinone/Resveratrol TQ
46.03 μM
Resveratrol
64.54 μM		Hepatocellular carcinoma In vitroSignificant cell inhibition and increased caspase-3 cell inhibition and increase in caspase-3 indicating cell apoptosis
raised reactive oxygen species leading to decrease of glutathione		[162]
PiperineAlkaloids Piperine/ThymoquinonePiperine
425 μM
Thymoquinone
80 μM		Breast cancer In vivoInhibition of angiogenesis, induction of apoptosis, and shift toward T helper1 immune response decrease VEGF expression and increased serum INF-γ levels
angiogenesis inhibition, apoptosis induction, and shifting the immune response toward T helper1 response. 		[181]
EmodinAnthraquinonoe/phenolic compoundEmodin/berberine Emodin
5–20 μM
berberine
5–30 μM 		Breast cancerIn vitro Synergic inhibition of SIK3/mTOR pathway and induction of apoptosis Attenuated aerobic glycolysis and cell growth as well as induce cell death by suppressing the SIK3/mTOR/Akt signaling pathway [220]
ParthenolideSesquiterpene/germacranolide classParthenolide/ginsenoside compound kparthenolide 7.5 mg/kg
ginsenoside compound k 37.5 mg/kg		Lung cancer In vitro
In vivo 		Increased tumor targeting induce mitochondria-mediated lung cancer apoptosis[233]
Parthenolide/betulinic acid/honokiol/ginsenoside Rh2Parthenolide
20.5 mg/kg,
betulinic acid
20.3 mg/kg
Honokiol
20.7 mg/kg
ginsenoside Rh2
20 mg/kg		Lung cancerIn vitro
In vivo		Displayed a synergistic activity in liposome systems for lung cancer treatmentcocktail liposome systems may provide a more efficient and safer treatment for lung cancer.[234]
LuteolinDigitoflavone/flavonoid Luteolin/BaicaleinLuteolin
2.5, 5, 12.5, 25, 50, 80 and 100 mM
Baicalein
2.5, 5, 12.5, 25, 50, 80 and 100 mM		Colorectal adenocarcinoma In vitro Synergic growth inhibition inhibit cancer cells proliferation[255]
Luteolin
10 or 20 μM
Quercetin
10, 20, and 40 μM		Cervical cancerIn vitroReduction in ubiquitin E2S expression led eventually to metastatic inhibition of cervical cancerinhibited UBE2S expression[247]
Luteolin/HesperidinHesperidin
100 μg/mL
Luteolin
100 μg/mL		Breast cancer In vitroInduced cell cycle arrest by mediating apoptosis and downregulation the miR-21 expression inhibition of cell proliferation, migration, and invasion
reduced cell viability
accumulation of apoptotic cells into the G0/G1 and sub-G1 cell cycle phases
induced apoptosis through the intrinsic and extrinsic pathways, down-regulated anti-apoptotic, Bcl-2, and upregulated pro-apoptotic, Bax
downregulated the expression of miR-21 and upregulated that of miR-16 and -34a in MCF-7		[249]
Luteolin/SilibininLuteolin
20 µM
Silibinin
50 µM		Glioblastoma In vitroSynergic inhibition of cell proliferation, migration, and invasion inhibition of cell migration
block angiogenesis
block survival pathways leading to induction of apoptosis.		[247]
QuercetinFlavonol/flavonoidQuercetin/CurcuminQuercetin
20 µM
Curcumin
10 µM 		Breast cancerIn vitroAltered the BRCA1 deficiency and therefore augment the activity of anti-cancer drugssynergistic action was observed in modulating the BRCA1 level and in inhibiting the cell survival and migration of TNBC cell lines[258]
Quercetin 11.39, 0.419 µM,
Curcumin 2.85, 53.89 µM		Myeloid leukemiaIn vitro Enhanced apoptotic effect increasing ROS productionact indirectly on inhibition of STAT3 in a number of leukaemia cell lines (HL-60, U-937 and K562)[259]
Quercetin/Resveratrol Quercetin
10 µM
Resveratrol
10 µM 		Oral cancerIn vitroCell growth inhibition, stimulation of apoptosis also it had been noticed to downregulate Histone deacetylase (HDAC)1, HDAC3, and HDAC8 Cell Growth Inhibition, DNA Damage, Cell Cycle Arrest, and Apoptosis in Oral Cancer Cells[260]
Quercetin 2 μg/mL
Resveratrol 50 μg/mL		Skin cancer In vivo
Ex vivo		Synergistic effect over the use of single drugs dual drug-loaded nanostructured lipid carrier (NLC) gel of quercetin and resveratrol enhanced their disposition in dermal and epidermal layers[261]
Quercetin/ThymoquinoneQuercetin
22.49 µM
TQ
22.49 µM 		Non-small lung cancer In vitroDownregulated BcL2, and activated BAX protein reduce the expression of antiapoptotic protein Bcl2 and induce proapoptotic Bax, suggestive of sensitizing NSCLS cells toward apoptosis.[174]
Quercetin/LuteolinLuteolin
10 or 20 μM
Quercetin
10, 20, and 40 μM		Cervical cancer In vitro Lowered the ubiquitin E2S ligase (UBE2S) expressioninhibited UBE2S expression[248]
AnthocyaninsFlavylium/flavonoid Anthocyanins/luteolin Anthocyanins
Cyanidin-3-O-glucoside chloride
35 μmol/L
luteolin
10 μmol/L		Breast cancer
Colon cancer 		In vitro Increased apoptosis and inhibited proliferation inhibited proliferation and increased apoptosis[287]
Table
Table 2. Combination experimental design of natural compounds with conventional anticancer therapy and the outcomes of these studies.
Table 2. Combination experimental design of natural compounds with conventional anticancer therapy and the outcomes of these studies.
Natural CompoundCombination TherapyConcentration UsedType of Cancer Outcomes of the CombinationIntersecting MechanismReferences
CurcuminCurcumin/Paclitaxel Curcumin
5 µM
Taxol
5 nM		Cervical cancer Curcumin enhanced paclitaxel-induced apoptosis by increasing p53 expression, activation of caspase-3, 7, 8, and 9, cleavage of poly(ADP-ribose) polymerase (PARP), and cytochrome c releaseNon intersecting
Curcumin enhanced paclitaxel-induced apoptosis by down-regulation of Nuclear Factor-κB and the Serine/Threonine Kinase Akt 		[35,36]
Curcumin/DocetaxelCurcumin
20 μM
Docetaxel
10 nM 		Prostate cancer Reduced docetaxel-induced drug resistance and side effectsNon intersecting
curcumin enhances the efficacy of docetaxel treatment by inhibiting proliferation and inducing apoptosis through modulation of tumor-suppressor proteins, transcription factors and oncogenic protein kinases compared to each treatment alone		[38]
Curcumin/MetforminCurcumin
5–40 μM
Metformin
0.4–12 mM 		Prostate cancer Synergistic impact on growth inhibition by apoptotic induction than curcumin and metformin aloneApoptosis[40]
Curcumin/5-FU curcumin
5 µM
5-FU
0.1 µM 		Colorectal cancer Overcome the drug resistance caused by 5-FUNon-intersecting
Curcumin decreases cancer stem cells and making cancer cells more sensitive to 5-FU		[42]
Curcumin/CelecoxibCurcumin
10–15 μmol/L
Celecoxib
5 μmol/L		Colorectal cancer Inhibited cancer cell proliferationGrowth inhibition was associated with inhibition of proliferation and induction of apoptosis. Curcumin augmented celecoxib inhibition of prostaglandin E2 synthesis. The drugs synergistically down-regulated COX-2 mRNA expression.[43]
Curcumin/Cisplatin Curcumin
10 M
Cisplatin
10 M 		Bladder cancer Stimulated caspase-3 and overexpression phospho-mitogen-activated protein kinase (p-MEK) and phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) signaling activating caspase-3 and upregulating phospho-mitogen-activated protein kinase (p-MEK) and phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) signaling [44]
Curcumin/Doxorubicin Curcumin
5 M
Doxorubicin
0.4 mg/mL		Hodgkin lymphomaReduced cell growth by 79%reduced cell growth by 79%, whereas each drug alone reduced L540 cell growth by 44% and 23%[45]
ResveratrolResveratrol/TemozolomideResveratrol
12.5 mg/kg
Temozolomide
10 mg/kg TMZ		Malignant gliomaEnhanced temozolomide’s therapeutic efficacy by inhibiting ROS/ERK-mediated autophagy and improving apoptosis reduced tumor volumes by suppressing ROS/ERK-mediated autophagy and subsequently inducing apoptosis
protected glioma cells from apoptosis, thus improving the efficacy of chemotherapy for brain tumors. 		[78]
Resveratrol/DoxorubicinResveratrol
25 µM
Resveratrol
10–100 µM
Resveratrol
12.5 mg/kg		MelanomaInduced cell cycle disruption and apoptosis, resulting in decreased melanoma growth and increased mouse survival Non intersecting
resveratrol
inhibits the growth of a doxorubicin-resistant B16 melanoma cell subline (B16/DOX)
induced G1-phase arrest followed by the induction of apoptosis
reduced the growth of an established B16/DOX melanoma and prolonged survival (32% compared to untreated mice). 		[79]
GenisteinGenistein/5-FUgenistein
1.3 mg/day intraperitoneally
FU
60 mg/kg, intraperitoneally		Pancreatic cancerTumor cells were augmented by the addition of genistein, which increased both apoptosis and autophagyNon intersecting
Genistein can potentiate the antitumor effect of 5-FU by inducing apoptotic as well as autophagic cell death.		[99]
Genistein/Photofringenistein
(0, 50, 100 μM)
Photofrin
(0–50 μg/mL) 		Ovarian cancer
Thyroid cancer 		Enhanced the efficacy of photofrin-mediated photodynamic therapyNon intersecting
genistein sensitizes the activity of photodynamic therapy by photofrin in SK-OV-3 cells by inducing apoptosis through the activation of caspase-8 and caspase-3		[51]
Genistein/Estradiol Genistein
20 μM
Estradiol
20 μM		Human liver cancer Enhanced apoptosisEnhanced apoptosis[98]
EGCGEGCG/5-FUEGCG
50 μM
5-FU
10 μM		Colorectal cancerImproved tumor cell’s sensitivity to 5-FU through inhibition of 78-kDa glucose-regulated protein (GRP78), NF-KB, miR-155-p5 and multidrug resistance mutation 1 (MDR1) pathwaysNon intersecting
EGCG enhanced the chemo-sensitivity of 5-FU in low doses by inhibiting cancer proliferation, promoting apoptosis and DNA damage
EGCG blocked GRP78 expression, followed by enhancement of NF-κBand miR-155–5p level, which further inhibited the MDR1 expression and promoted the 5-FU accumulation in tumor cell		[87]
EGCG/Cisplatin EGCG
10 μM
Cisplatin
10 μM 		Ovarian cancerEnhanced cisplatin sensitivity in ovarian cancer by regulating the expression of copper and cisplatin influx transport which is well-known as copper transporter 1 (CTR1) DNA damage [125]
EGCG/TamoxifenEGCG
25 mg kg−1
Tamoxifen
75 μg kg−1		Breast cancer Decreased the expression of EGFR, mTOR, and CYP1BDecreased the expression of EGFR, mTOR, and CYP1B[126]
EGCG/Paclitaxel EGCG
20 μM
Paclitaxel
1 μM		Breast cancer EGCG had synergistically encouraged the effect of paclitaxel by enhancing the phosphorylation of c-Jun N-terminal kinase (JNK) induced 4T1 cells apoptosis[127]
EGCG/GefitinibEGCG
20 μM
Gefitinib
1.25 μM 		Non-small cell lung cancer Inhibition of epithelial-Mesenchymal transition (EMT), and blocking of mTOR pathwayinhibit proliferation of HCC827-Gef cells[128]
EGCG/Erlotinib EGCG
30 μM
Erlotinib
1 μM		Head and neck cancerenhanced apoptosis through the regulation of Bcl-2-like protein11(BIM) and B-cell lymphoma 2(Bcl-2)inhibiting the phosphorylation of ERK and AKT and expression
induces apoptosis of SCCHN cells by regulating Bim and Bcl-2 at the posttranscriptional level.		[129]
AllicinAllicin/Cisplatin Allicin
10 μg/mL
Cisplatin
2 μg/mL 		Lung cancer Allicin overcome hypoxia mediated cisplatin resistance by increasing ROS production shifts the mechanism of cell death towards more apoptosis
allicin induced increase in ROS accumulation thus enhances cisplatin sensitivity even at low doses in A549 cells.		[144]
Allicin/5-FUAllicin
5 mg/kg/d; every two days for 3 weeks
5-FU
20 mg/kg/d
5 consecutive days		Hepatic cancer Improved its sensitivity in hepatic cancer cells due to induction of apoptosis by ROS-mediated mitochondrial pathwaysincreased intracellular reactive oxygen species (ROS) level, reduced mitochondrial membrane potential (ΔΨm), activated caspase-3 and PARP, and down-regulated Bcl-2 [154]
Allicin/AdriamycinAllicin
25 μg/mL
Adriamycin
2.5 μg/mL		Gastric cancerInhibited the proliferation and induced apoptosisinduced apoptosis and inhibited proliferation[148]
Allicin/Tamoxifen Allicin
10 nM
Tamoxifen
1 μM		Breast cancer Improved the effectiveness of tamoxifenNon intersecting
Allicin in MCF-7 cells enhances the effectiveness of tamoxifen in the presence and absence of 17-b estradiol		[149]
ThymoquinoneThymoquinone/DoxorubicinFor most experiments
Thymoquinone
10 µM TQ
Doxorubicin
50 nM
for 24 h
for the treatment of HuT102 cells for 48 h
Thymoquinone
40 µM
Doxorubicin
100 nM 		Adult T-cell leukemia Increased ROS production resulting in disruption of the mitochondrial membraneIncreased ROS production resulting in disruption of the mitochondrial membrane
inhibition of cell viability and increased sub-G1 cells
reduced tumor volume		[169]
Thymoquinone/CisplatinThymoquinone 20 mg·kg−1 oral
cisplatin 2 mg·kg−1 ip		Hepatocellular carcinomaImproved the effectiveness of Cisplatin via controlling the GRP78/CHOP/caspase-3 pathwayreduced the elevated GRP78 and induced CHOP-mediated apoptosis in the diseased liver tissues
normalized alpha-fetoprotein (AFP) levels and improved liver functions		[167]
Thymoquinone/Cisplatin/PentoxifyllinThymoquinone
i.p. (20 mg/kg)
Cisplatin
7.5 mg/kg twice
Pentoxifyllin
s.c. route 15 mg/kg		Breast carcinomaEnhance the effect of the treatment by Notch pathway suppressionreduced Notch1, Hes1, Jagged1, β-catenin, TNF-α, IL-6, IFN-γ, and VEGF with increment in IL-2, CD4, CD8, and apoptotic cells
Notch suppression.		[170]
Thymoquinone/Paclitaxel 100:1 μM of TQ with PTX Breast cancerincreased the rate of apoptotic/necrotic cell deathNon intersecting
Thymoquinone does not improve Paclitaxel potency against MCF-7 or T47D cells and apparently antagonizes its killing effects. However, TQ significantly abolishes tumor-associated resistant cell clones
Thymoquinone enhanced Paclitaxel induced cell death including autophagy
TQ significantly increased the percent of apoptotic/necrotic cell death in T47D cells after combination with paclitaxel
induced a significant increase in the S-phase cell population		[168]
PiperinePiperine/Paclitaxel5:1Breast cancer Synergistic anticancer effectNon intersecting
piperine can improve the bioavailability of paclitaxel and can potentiate the antitumor effect of paclitaxel		[189]
Piperine/hesperidin/bee venom/TamoxifenPiperine
34.89 μg/mL
Hesperidin
12.14 μg/mL
bee venom
10.19 μg/mL
Tamoxifen
2.98 μg/mL		Breast cancerEnhance the anti-cancer effects of tamoxifenEnhance the anti-cancer effects of tamoxifen[190]
Piperine/Doxorubicin Piperine
50 µM
Doxorubicin
10 µM 		Breast cancerInhibited tumor growth Piperine enhanced the cytotoxicity effect of doxorubicin[191]
Piperine/Docetaxel Piperine
50 mg/kg p.o.
Docetaxel
12.5 mg/kg		Prostate cancerImproved the antitumor efficacy of docetaxelImproved Anti-Tumor Efficacy Via Inhibition of CYP3A4 Activity[192]
EmodinEmodin/SorafenibEmodin
20 μM
Sorafenib
0.5 μM and 1 μM 		Hepatocellular carcinomaImproving the anti-cancer effect of sorafenib by increasing apoptosis and cell cycle arrest Non intersecting
emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib		[207]
Emodin/AfatinibEmodin
50 mg/kg/day for 4 weeks
Afatinib
50 mg/kg/day for 4 weeks;		Pancreatic cancer Inhibited cell proliferationRegulating the Stat3 expression.[216]
Emodin/CisplatinEmodin
A549 cells:5 µM
H460 cells, 2.5 µM
Cisplatin
A549: 8, 10 and 15 µM
H460 cells:2, 4, 6, 8 and 10 µM		Lung adenocarcinomaIncreased cisplatin sensitivity through P-glycoprotein downregulationNon intersecting
Emodin inhibited the proliferation of A549 and H460 cells
emodin enhanced cisplatin-induced apoptosis and DNA damage in A549 and H460 cells
emodin can increase A549 and H460 cell sensitivity to cisplatin by inhibiting Pgp expression		[219]
Emodin/Paclitaxel Emodin 10 μM
Paclitaxel 4 μM		Non-small cell lung cancer Enhanced the antiproliferative effect of paclitaxel Inhibited the proliferation of A549 cells [212]
Emodin/Gemcitabin Emodin
40 μM
Gemcitabine
20 μM		Pancreatic cancerEmodin inhibited IKKβ/NF-κB signaling pathway and reverses Gemcitabine resistanceIncrease the apoptosis rate[213]
Emodin/Endoxifen Emodin
0, 15, 30, 60 µM
Endoxifen
0, 2, 4 µM		Breast cancer Elevation of cyclin D1 and phosphorylated extracellular signal-regulated kinase (pERK) Emodin attenuated tamoxifen’s treatment effect via cyclin D1 and pERK up-regulation in ER-positive breast cancer cell lines.[294,299]
ParthenolideParthenolide/EpirubicinParthenolide
2.5, 0.75 and 0.2 µM
Epirubicin
(9, 7, and 5 µM		Breast cancerimproved cytotoxicity and apoptosis as well as reduced the undesirable side effectsUp-regulated the expression of Bax as a pro-apoptotic gene in MDA-MB cells
down-regulated the expression of Bcl2 as an anti-apoptotic gene in MDA-MB cells
increasing the fracture of caspase 3 and improving the apoptosis pathway		[221]
Parthenolide/Indocyanine Breast cancerSynergistic antitumor activityMore ROS-mediated killing of the tumor cells by exerting a synergistic effect for treating triple-negative breast cancer[270]
Parthenolide/Arsenic trioxideParthenolide
1 μg/mL
Arsenic trioxide
2 µM		Adult T-cell leukemia/lymphomaEnhanced the activity Non intersecting
parthenolide significantly enhanced the toxicity of ATO in MT2 cells.		[231]
Parthenolide/Balsalazide Parthenolide
5 and 10 μmol/L
Balsalazide
20 mmol/L 		Colorectal cancerImproved the anticancer activity via blocking NF-κB activation Exhibits synergistic suppression of NF-κB and NF-κB–regulated gene products that are associated with apoptosis, proliferation, invasion, angiogenesis, and inflammation [232]
LuteolinLuteolin/Cisplatin Luteolin
0, 10, 50, 100 μM
Cisplatin
2 μg/mL 		Ovarian cancerSignificantly sensitized the antineoplastic effect of cisplatin by initiating apoptosis and inhibiting cell invasion and migration Suppressing CAOV3/DDP cell growth and metastasis
inducing apoptosis by decreasing Bcl-2 expression. 		[245]
Luteolin/5-FULuteolin:5-fluorouracil
10:1, 20:1, 40:1
luteolin:100, 50, 25, 12.5, 6.25, 3.125 µM
5-FU: 10, 5, 2.5, 1.25, 0.5, 0.25 µg/mL		Hepatocellular carcinoma synergistic anticancer effect Apoptosis induction and metabolism [244]
QuercetinQuercetin/CisplatinQuercetin
100 μM
cisplatin
5 μg/mL		Oral squamous cell carcinomaInhibition of NF-κB thus downregulating of X-linked inhibitor of apoptosis protein(xIAP)Induced apoptosis in human OSCC (cell lines Tca-8113 and SCC-15) by down-regulating NF-κB[273]
Quercetin
50 μM
cisplatin
10 μM		Hepatocellular carcinomapotentiated the growth suppression effect of cisplatinInducing growth suppression and apoptosis in HepG2 cells[268]
quercetin
15 μM
cisplatin
10 μM		Cervical cancer Induced apoptosis by downregulation of MMP2, METTL3, P-Gp and ezrin productionPromoting apoptosis and inhibiting proliferation, migration and invasion of cervical cancer cells[262]
Quercetin/Tamoxifen Quercetin
50 μM
Tamoxifen
10–6 mol/L		Breast cancer Enhanced the activity Proliferation inhibition and apoptosis in
MCF-7Ca/TAM-R cells		[264]
Quercetin/Vincristine Vincristine
50 mg
Quercetin
50 mg		Lymphoma Potentiated the effect of vincristineSynergistic effect through lipid-polymeric nanocarriers (LPNs) for the
lymphoma combination chemotherapy		[269]
Quercetin/Doxorubicin Quercetin
0.7 μM
Doxorubicin
2 μg/mL		Breast cancerSuppression of efflux receptors (BCRP, P-gp, MRP1), and reduced the side effects of doxorubicinDown-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1 and attenuating the toxic side effects of high dose doxorubicin to non-tumor cells [265]
Quercetin and Doxorubicin
5 mg/kg		Gastric cancer Improved the efficacyImproved the efficacy of gastric carcinoma chemotherapy[267]
Doxorubicin
0.75 μM
Quercetin
230 μM		Breast cancer Improved the efficacyInduction of apoptosis in cancer cells[266]
Quercetin/RadiotherapyTheranostic system (CQM ) 50 μmBreast cancer Improved the tumor targeting and radiotherapy treatmentPromoted tumor cell apoptosis[272]
Quercetin/Paclitaxel Quercetin
20 µM
Paclitaxel
5 nM		Prostate cancer Improved efficacy by by ROS production, induction of apoptosis, preventing cell migration and causing cell arrest in G2/M phaseInduction of apoptosis
cell arrest in G2/M phase
ROS production
Preventing cell migration		[270]
Quercetin
2, 10, 20 mg/kg
Paclitaxel
40 mg/kg		Breast cancer had enhanced the multi-drug resistance in breast cancer by decreasing P-gp expressionLower IC50 value,
higher apoptosis rate, obvious G2M phase arrest as well as stronger microtubule
destruction in MCF-7/ADR cells		[271]
AnthocyaninsAnthocyanins/ 5-FUCaco2 cells
BRB Anthocyanins 50 μg/mL
5-FU 25 μM or 50 μM
SW480 cells
BRB Anthocyanins 50 μg/mL
5-FU 16 μM or 32 μM		Colorectal cancerdecreased the proliferation and migration of tumor cellsDecreased number of tumors
decreased the proliferation 		[287]
Anthocyanins/CisplatinAIMs Anthocyanins
400 µg/mL
Cisplatin
5 μg/mL		Breast cancer advanced the sensitivity of cisplatin by inhibiting Akt and NF-κB activity Non intersecting
Anthocyanins isolated from Vitis coignetiae Pulliat (Meoru in Korea) (AIMs) Enhances Cisplatin Sensitivity in MCF-7 Human Breast Cancer Cells through Inhibition of Akt and NF-κB Activation		[289]
Anthocyanins/DoxorubicinAnthocyanins
1–25 μg/mL
Doxorubicin
5 μM		Breast cancer decreased doxorubicin cardiac toxicitySmoothies containing mixtures of Citrus sinensis and Vitis vinifera L. cv. Aglianico N, two typical fruits of the Mediterranean diet decreased doxorubicin cardiac toxicity[291]
Anthocyanins/Trastuzumab C3G
5 μg/mL
Trastuzumab
5 μg/mL		Breast cancer Improved trastuzumab apoptotic effectNon intersecting
Improved trastuzumab apoptotic effect		[294]
C3G (1 mg/mL) or P3G (1 mg/mL)Breast cancerOvercome trastuzumab-resistant cells due to the decrease in HER2, AKT and MAPK activitiesNon intersecting
Anthocyanin overcome trastuzumab-resistant cells due to the decrease in HER2, AKT and MAPK activities
inhibits invasion and migration of trastuzumab-resistant human breast cancer cells 		[295]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Talib, W.H.; Awajan, D.; Hamed, R.A.; Azzam, A.O.; Mahmod, A.I.; AL-Yasari, I.H. Combination Anticancer Therapies Using Selected Phytochemicals. Molecules 2022, 27, 5452. https://doi.org/10.3390/molecules27175452

AMA Style

Talib WH, Awajan D, Hamed RA, Azzam AO, Mahmod AI, AL-Yasari IH. Combination Anticancer Therapies Using Selected Phytochemicals. Molecules. 2022; 27(17):5452. https://doi.org/10.3390/molecules27175452

Chicago/Turabian Style

Talib, Wamidh H., Dima Awajan, Reem Ali Hamed, Aya O. Azzam, Asma Ismail Mahmod, and Intisar Hadi AL-Yasari. 2022. "Combination Anticancer Therapies Using Selected Phytochemicals" Molecules 27, no. 17: 5452. https://doi.org/10.3390/molecules27175452

APA Style

Talib, W. H., Awajan, D., Hamed, R. A., Azzam, A. O., Mahmod, A. I., & AL-Yasari, I. H. (2022). Combination Anticancer Therapies Using Selected Phytochemicals. Molecules, 27(17), 5452. https://doi.org/10.3390/molecules27175452

Article Metrics

Back to TopTop